RESULT_COUNT: 559,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
CLVS,CLVS:UW,BBG001S2DKJ3,Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?,2017-10-20 17:05:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D5gzbKs51c0/is-a-beat-in-the-cards-for-vertex-vrtx-in-q3-earnings-cm862675,We expect Vertex Pharmaceuticals Inc VRTX to beat expectations when it reports its third quarter 2017 results on Oct 25 after the market closes Year to date Vertex s shares have soared 109 9 while the industry has recorded an increase of 12 1 Vertex s track record has
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review,2017-10-19 15:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LH0cVOpVksY/astrazenecas-snda-for-two-cancer-drugs-gets-priority-review-cm861975,AstraZeneca plc AZN and partner Merck MRK announced that the FDA has granted priority review to its supplemental New Drug Application sNDA for Lynparza With this sNDA AstraZeneca and Merck are looking to expand the label of Lynparza presently marketed for advanced ovarian cancer to
CLVS,CLVS:UW,BBG001S2DKJ3,Gilead Sciences on the Street: Analyst Recommendations in October,2017-10-17 12:39:06 +0000,http://finance.yahoo.com/r/0e7aeab2-fa2e-31f9-8688-7e92569f163a/gilead-sciences-on-the-street-analyst-recommendations-in-october?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."""
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-10-17 12:05:30 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120530454.html?.tsrc=rss,Clovis Oncology Inc NASDAQ/NGS:CLVS
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-10-16 12:04:50 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120450501.html?.tsrc=rss,Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The net inflows of $2.64 billion over the last one-month into ETFs that hold CLVS are not among the highest of the last year and have been slowing.
CLVS,CLVS:UW,BBG001S2DKJ3,SPDR S&P Biotech ETF Experiences Big Outflow,2017-10-13 16:12:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y2YeC8dLonY/spdr-sp-biotech-etf-experiences-big-outflow-cm859407,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 65 4 million dollar outflow that s a 1 5 decrease week over week from 49 500 000
CLVS,CLVS:UW,BBG001S2DKJ3,"Biotech Stock Roundup: Amgen&apos;s Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit",2017-10-11 12:07:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-amgen-apos-120712520.html?.tsrc=rss,"With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi&apos;s win in the PCSK9 litigation."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca,2017-10-10 14:50:02 +0000,https://finance.yahoo.com/news/clovis-clvs-submits-snda-ovarian-145002989.html?.tsrc=rss,Clovis submitted a sNDA to the FDA for expansion of Rubraca&apos;s label in maintenance treatment for ovarian cancer patients who are in a partial or complete response to platinum-based chemotherapy.
CLVS,CLVS:UW,BBG001S2DKJ3,"CLVS Seeks New Use For Rubraca, TNDM Effects Reverse Stock Split, MDXG On Watch",2017-10-10 01:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pJZqDJtQ2_Q/clvs-seeks-new-use-for-rubraca-tndm-effects-reverse-stock-split-mdxg-on-watch-20171010-00022,"CLVS Seeks New Use For Rubraca, TNDM Effects Reverse Stock Split, MDXG On Watch"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer,2017-10-09 20:05:00 +0000,https://finance.yahoo.com/news/clovis-oncology-submits-supplemental-drug-200500835.html?.tsrc=rss,"Clovis Oncology announced today that the company has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy."
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-10-06 12:03:33 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120333157.html?.tsrc=rss,Clovis Oncology Inc NASDAQ/NGS:CLVS
CLVS,CLVS:UW,BBG001S2DKJ3,"XBI, CLVS, SRPT, PBYI: Large Inflows Detected at ETF",2017-10-05 16:49:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gunbgtXORhM/xbi-clvs-srpt-pbyi-large-inflows-detected-at-etf-cm855842,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 101 6 million dollar inflow that s a 2 4 increase week over week in outstanding
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-10-05 12:03:28 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120328021.html?.tsrc=rss,Clovis Oncology Inc NASDAQ/NGS:CLVS
CLVS,CLVS:UW,BBG001S2DKJ3,Cancer-Cure Makers Make Great Takeover Stocks,2017-10-04 15:40:00 +0000,http://finance.yahoo.com/r/1e7d01db-ac15-3e75-87c8-b95756b3c226/cancer-cure-makers-make-great-takeover-stocks?utm_source=yahoo&utm_medium=partner&utm_campaign=yahoofeed&partner=yahoomag&yptr=yahoo&.tsrc=rss,This company's impressive technology portfolio make it a great acquisition candidate.
CLVS,CLVS:UW,BBG001S2DKJ3,These Biotechs Slump As Report Suggests Discounting Their Drugs,2017-10-03 20:22:45 +0000,http://finance.yahoo.com/r/dfdfffc8-8026-3874-9313-8a5181066323/these-biotechs-slump-as-report-suggests-discounting-their-drugs?src=A00220&yptr=yahoo&.tsrc=rss,"AstraZeneca and Tesaro stocks were in a slump Tuesday, a day after an institute doubted the cost-effectiveness of their cancer drugs."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Scores Relative Strength Rating Upgrade,2017-09-28 14:44:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ExXVg4f2oQA/clovis-oncology-scores-relative-strength-rating-upgrade-cm852533,Clovis Oncology CLVS saw a positive improvement to its Relative Strength RS Rating on Thursday with an upgrade from 88 to 92 ibd display video id 449419 width 50 float left autostart true IBD s unique RS Rating identifies market leadership by showing how
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Scores Relative Strength Rating Upgrade,2017-09-28 07:00:00 +0000,http://finance.yahoo.com/r/dc296099-ca30-3e0b-a1ca-b07a37522471/clovis-oncology-scores-relative-strength-rating-upgrade?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Clovis Oncology shows improving technical performance.
CLVS,CLVS:UW,BBG001S2DKJ3,"XBI, CLVS, EXEL, SRPT: Large Outflows Detected at ETF",2017-09-27 16:55:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jW-pUueK1X8/xbi-clvs-exel-srpt-large-outflows-detected-at-etf-cm851981,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 49 9 million dollar outflow that s a 1 2 decrease week over week from 48 950 000
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-09-26 12:03:46 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120346731.html?.tsrc=rss,Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : September 25, 2017",2017-09-25 12:10:11 +0000,http://finance.yahoo.com/r/5b46fac7-b668-36b4-bcb3-566e62e8a1d4/clovis-oncology-inc-breached-its-50-day-moving-average-in-a-bullish-manner-clvs-us-september-25-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Clovis Oncology, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher,2017-09-19 14:41:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tt1W2X58cbQ/clovis-oncology-clvs-in-focus-stock-moves-105-higher-cm847648,Clovis Oncology Inc CLVS was a big mover last session as the company saw its shares rise nearly 11 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher,2017-09-19 12:51:12 +0000,https://finance.yahoo.com/news/clovis-oncology-clvs-focus-stock-125112535.html?.tsrc=rss,"Clovis Oncology (CLVS) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes."
CLVS,CLVS:UW,BBG001S2DKJ3,Today's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology,2017-09-19 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000236.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 19, 2017 / Dimension Therapeutics and Clovis Oncology both saw big gains on Monday. It was takeover buzz that set Clovis shares moving north while Dimension soared ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"NBRV Leaps On Study Data, CSII Takes A Hit, CLVS Abuzz, New Dimension For DMTX",2017-09-18 23:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JFcEx12x7zc/nbrv-leaps-on-study-data-csii-takes-a-hit-clvs-abuzz-new-dimension-for-dmtx-20170918-01351,"NBRV Leaps On Study Data, CSII Takes A Hit, CLVS Abuzz, New Dimension For DMTX"
CLVS,CLVS:UW,BBG001S2DKJ3,"Health Care Sector Update for 09/18/2017: CLVS,LLY,ITUS,AEMD",2017-09-18 20:36:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L8MIskxQnAY/health-care-sector-update-for-09182017-clvsllyitusaemd-cm847389,Top Health Care StocksTop Health Care Stocks JNJ 0 74 JNJ 0 74 PFE 0 35 PFE 0 35 ABT 0 56 ABT 0 56 MRK 0 30 MRK 0 30 AMGN 0 46 AMGN 0 46 Health care stocks were ending little changed this afternoon with the NYSE Health Care Index rising less than 0 1 while shares of health
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Up 10% On Double Normal Volume,2017-09-18 20:02:00 +0000,http://finance.yahoo.com/r/761d0110-e26a-3e01-9146-dec8b4babedf/clovis-up-10-on-double-normal-volume?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Last month, Todd Hagopian named Clovis Oncology as 1 of 3 takeover candidates. Today CLVS is trading around $76, up more than 10% on double its' normal daily volume making it the third largest position in Todd's Biotech fund."
CLVS,CLVS:UW,BBG001S2DKJ3,"So Much PARP Inhibitor Deal Hype, So Little Payoff",2017-09-18 19:44:30 +0000,http://finance.yahoo.com/r/cf22bce6-072b-38d5-8b81-cbe2c0c70467/clovis-deal-rumors-so-much-parp-inhibitor-hype-so-little-payoff?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"After a year of hype with little payoff, an FDA ruling means M&A makes even less sense."
CLVS,CLVS:UW,BBG001S2DKJ3,TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion,2017-09-18 16:41:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WMbS6WM3VRU/tesaro-ovarian-cancer-drug-zejula-gets-positive-chmp-opinion-cm847213,TESARO Inc 160 TSRO announced that the Committee for Medicinal Products for Human Use CHMP has recommended marketing approval of its ovarian cancer drug Zejula niraparib TESARO is seeking approval of the oral once daily poly ADP ribose polymerase PARP inhibitor as monotherapy
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Inc. (CLVS) Has Broken Out Of Today's Range,2017-09-18 10:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cgjVPuzY060/clovis-oncology-inc-clvs-has-broken-out-of-todays-range-20170918-00780,Clovis Oncology Inc. (CLVS) Has Broken Out Of Today's Range
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet,2017-09-13 10:00:00 +0000,https://finance.yahoo.com/news/clovis-oncology-rucaparib-ariel3-study-100000325.html?.tsrc=rss,"Clovis Oncology, Inc. announced that comprehensive data from the Phase 3 ARIEL3 study of rucaparib for maintenance treatment of advanced ovarian cancer were published online today in The Lancet."
CLVS,CLVS:UW,BBG001S2DKJ3,Should You Keep Your Portfolio Healthy with Biotech ETFs?,2017-09-12 19:08:07 +0000,https://finance.yahoo.com/news/keep-portfolio-healthy-biotech-etfs-190807308.html?.tsrc=rss,Biotech ETFs are riding high on research and developments and FDA approvals.
CLVS,CLVS:UW,BBG001S2DKJ3,Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology,2017-09-11 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000000.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 11, 2017 / U.S. markets, the dollar and bond yields posted weekly losses on the combination of weather concerns and rising geopolitical tensions between the U.S. and ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It",2017-09-11 10:30:00 +0000,http://finance.yahoo.com/r/5802cdab-5f58-33a8-a568-a030d3c38294/rubraca-a-parp-inhibitor-active-in-ovarian-cancer-might-control-pancreatic-cancer-even-if-it-doesnt-cure?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,Rubraca Keeps Many Ovarian Cancers In Check. Could It Work As Maintenance Treatment In Pancreatic Cancer?
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers,2017-09-08 14:39:00 +0000,http://finance.yahoo.com/r/39525ed3-b442-31a9-90d9-7c4378635c06/clovis-rises-on-comprehensive-phase-3-data-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The company is scheduled Friday afternoon to present comprehensive data from its Phase 3 study of rucaparib at the European Society for Medical Oncology Congress in Madrid.
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017,2017-09-07 22:05:00 +0000,https://finance.yahoo.com/news/clovis-oncology-presents-comprehensive-dataset-220500689.html?.tsrc=rss,"Clovis Oncology, Inc. announced the first presentation of a comprehensive dataset from its Phase 3 ARIEL3 study of rucaparib at the 2017 European Society for Medical Oncology Congress taking place in Madrid."
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Fell 7.1% in August,2017-09-07 21:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-aYpYURTjk/why-clovis-oncology-fell-71-in-august-cm842619,What happened Shares of Clovis Oncology NASDAQ CLVS a commercial stage biotech focused on cancer fell more than 7 in August according to data from S amp P Global Market Intelligence The decline was owed to the company sharing good and bad news with investors during in
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Fell 7.1% in August,2017-09-07 20:18:00 +0000,http://finance.yahoo.com/r/093c4beb-9793-3049-887b-46b24aeec19f/why-clovis-oncology-fell-71-in-august.aspx?yptr=yahoo&.tsrc=rss,Shares retreated after the company reported mixed quarterly results.
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound?,2017-09-07 11:51:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/95Fl-PfCaIc/clovis-clvs-down-81-since-earnings-report-can-it-rebound-cm842069,It has been about a month since the last earnings report for Clovis Oncology Inc CLVS Shares have lost about 8 1 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a breakout Before
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound?,2017-09-07 09:12:09 +0000,https://finance.yahoo.com/news/clovis-clvs-down-8-1-091209556.html?.tsrc=rss,Clovis (CLVS) reported earnings about a month ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-09-06 12:01:51 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120151234.html?.tsrc=rss,"Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last month, ETFs holding CLVS are favorable, with net inflows of $2.63 billion."
CLVS,CLVS:UW,BBG001S2DKJ3,"Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition",2017-09-02 14:20:00 +0000,http://finance.yahoo.com/r/7fcc7744-73dd-3685-998e-bce8e6bc7a72/more-immunotherapy-buyouts-likely-after-kite-sale.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,More Immunotherapy Buyouts Likely After Kite Sale
CLVS,CLVS:UW,BBG001S2DKJ3,"After Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next?",2017-08-30 18:58:00 +0000,http://finance.yahoo.com/r/c083cece-8807-386e-9340-f0f451ee637b/after-gileads-acquisition-of-kite-who-gets-gobbled-up-next?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"After Pfizer outbid Gilead for Medivation last September, Todd Hagopian named 4 companies Gilead might go after next. Kite Pharma, then trading at about $55, was among them. On Monday, Gilead acquired KITE for $180 per share. If you missed KITE, who might get gobbled up next?"
CLVS,CLVS:UW,BBG001S2DKJ3,Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal,2017-08-30 14:53:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nq-rcq0Sdzk/junobluebird-hot-acquisition-targets-after-kitegilead-deal-cm839092,Biotech giant Gilead Sciences Inc s GILD 11 8 billion deal to buy CAR T cancer therapy designer Kite Pharma Inc KITE has made two other leading independent CAR T developers Juno Therapeutics Inc JUNO and Bluebird Bio Inc BLUE hot takeover targets Terms of the Gilead
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress,2017-08-30 12:00:00 +0000,https://finance.yahoo.com/news/clovis-oncology-present-comprehensive-dataset-120000160.html?.tsrc=rss,"Clovis Oncology, Inc. today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 European Society for Medical Oncology Congress taking place September 8-12, 2017 in Madrid, Spain."
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why Clovis Stock Is Up Almost 60% So Far in 2017,2017-08-23 22:37:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ktsBJoVZK2E/heres-why-clovis-stock-is-up-almost-60-so-far-in-2017-cm836233,Shares of Clovis Oncology Inc CLVS have witnessed a continuous upside this year Shares of this small biotech company are up 62 3 so far this year outperforming the 7 2 increase registered by the industry 160 during this period Let s analyze the factors that have driven the rally so
CLVS,CLVS:UW,BBG001S2DKJ3,Here&apos;s Why Clovis Stock Is Up Almost 60% So Far in 2017,2017-08-23 20:59:08 +0000,https://finance.yahoo.com/news/apos-why-clovis-stock-almost-205908853.html?.tsrc=rss,Clovis Oncology (CLVS) stock is on the rise. The company&apos;s only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-08-23 12:04:03 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120403765.html?.tsrc=rss,"Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last month, ETFs holding CLVS are favorable, with net inflows of $2.66 billion."
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro: Losing Its Edge?,2017-08-18 22:33:00 +0000,http://finance.yahoo.com/r/811a1dff-85c7-3abe-ad3b-4246de1671e5/tesaro-losing-its-edge-1503088809?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK).  The two drugs belong to a class known as PARP inhibitors.  Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA."
CLVS,CLVS:UW,BBG001S2DKJ3,Ovarian Cancer Market Still Up For Grabs,2017-08-18 20:27:00 +0000,http://finance.yahoo.com/r/64a747af-2f4e-32c8-945b-4a168b4ac8ab/ovarian-cancer-market-still-up-for-grabs-1503088077?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients.  Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment."
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion,2017-08-18 15:42:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qv2SmLyIZY4/astrazenecamercks-lynparza-gets-fda-nod-for-label-expansion-cm833892,AstraZeneca plc AZN and partner Merck amp Co Inc MRK announced that the FDA has approved a new tablet formulation for ovarian cancer drug Lynparza while also broadening its U S label AstraZeneca s shares are up 11 5 so far this year comparing unfavorably with an increase of 13 7
CLVS,CLVS:UW,BBG001S2DKJ3,Analysts’ Recommendations for Bristol-Myers Squibb in August 2017,2017-08-18 11:39:11 +0000,http://finance.yahoo.com/r/62ccc48c-e2ea-3300-9a0b-da4feab35f38/analysts-recommendations-for-bristol-myers-squibb-in-august-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : August 17, 2017",2017-08-17 00:16:59 +0000,http://finance.yahoo.com/r/5101773a-f1c1-334b-b5c8-716463820345/clovis-oncology-inc-value-analysis-nasdaqclvs-august-17-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Clovis Oncology, Inc. a score of 11. Our analysis is based on comparing Clovis Oncology, Inc. with the following peers – BioMarin Pharmaceutical Inc., Celgene Corporation, TESARO, Inc., AbbVie, Inc., Eli Lilly and Company, Pfizer Inc., Astrazeneca PLC Sponsored ADR, Johnson & Johnson, Dare Bioscience, Inc. and ... Read more
<b>(Read more...)</b>"
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-08-16 12:03:20 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120320976.html?.tsrc=rss,Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  ETFs that hold CLVS had net inflows of $376 million over the last one-month.
CLVS,CLVS:UW,BBG001S2DKJ3,"Boxer Capital, LLC Buys Macrogenics Inc, G1 Therapeutics Inc, iPath S&P 500 VIX Short Term ...",2017-08-15 20:35:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CeIaXgeW0OY/boxer-capital-llc-buys-macrogenics-inc-g1-therapeutics-inc-ipath-sp-500-vix-short-term-cm832468,Boxer Capital LLC New Purchases MGNX GTHX VXX Added Positions PTCT LJPC SNSS SGEN Reduced Positions CLVS BPMC AVXS ESPR BGNE AQXP CBAY ONTX Sold Out ALNY ALXN ALDX ANAB AKTX ARDM NVET New Purchases MGNX
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses",2017-08-15 15:42:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XKIdC7gfMzg/clovis-clvs-focuses-on-label-expansion-rubraca-impresses-cm832221,We issued an updated research report on Boulder CO based Clovis Oncology Inc CLVS on Aug 14 Rubraca has shown impressive growth trend in 2017 on the back of the company s commercialization efforts Rubraca sales doubled sequentially in the second quarter Rubraca sales were 14 6 million
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses",2017-08-15 13:20:01 +0000,https://finance.yahoo.com/news/clovis-clvs-focuses-label-expansion-132001218.html?.tsrc=rss,"Clovis Oncology (CLVS) reported significant increase in Rubraca sales in the second quarter. Moreover, the company is focused on expanding Rubraca&apos;s label in second-line ovarian cancer."
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-08-14 12:01:51 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120327451.html?.tsrc=rss,"Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $503 million."
CLVS,CLVS:UW,BBG001S2DKJ3,Edited Transcript of CLVS earnings conference call or presentation 2-Aug-17 8:30pm GMT,2017-08-13 12:10:46 +0000,https://finance.yahoo.com/news/edited-transcript-clvs-earnings-conference-035145657.html?.tsrc=rss,Q2 2017 Clovis Oncology Inc Earnings Call
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-08-12 12:03:07 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120307032.html?.tsrc=rss,"Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $338 million."
CLVS,CLVS:UW,BBG001S2DKJ3,"XBI, EXEL, ALXN, CLVS: ETF Outflow Alert",2017-08-11 16:36:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hKewXWR9bgA/xbi-exel-alxn-clvs-etf-outflow-alert-cm830991,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 63 3 million dollar outflow that s a 1 8 decrease week over week from 46 500 000
CLVS,CLVS:UW,BBG001S2DKJ3,See what the IHS Markit Score report has to say about Clovis Oncology Inc.,2017-08-11 12:03:06 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120306729.html?.tsrc=rss,"Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $338 million."
CLVS,CLVS:UW,BBG001S2DKJ3,IHS Markit Score Update: Drop in demand for ETFs holding Clovis Oncology Inc is a negative sign for its shares,2017-08-10 12:04:18 +0000,https://finance.yahoo.com/news/ihs-markit-score-drop-demand-120418503.html?.tsrc=rss,"Short interest is moderate for CLVS with between 5 and 10% of shares outstanding currently on loan.  The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.  Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $717 million."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Enters Oversold Territory (CLVS),2017-08-09 22:34:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wgz9xalILII/clovis-oncology-enters-oversold-territory-clvs-cm829846,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech: Why Clovis And Tesaro Look Well Positioned,2017-08-09 13:02:00 +0000,http://finance.yahoo.com/r/cadae9b6-8b34-34c4-92db-e1103fd4e00d/biotech-why-clovis-and-tesaro-look-well-positioned-1502283741?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Morgan Stanley's Andrew Berens and his team have a note out on biotech, writing that investors should buy Clovis Oncology (CLVS) and Tesaro (TSRO) ahead of any labeling decision by the Food and Drug Administration for AstraZeneca's (AZN) Lynparza breast cancer drug.  Berens writes that he expects the most likely outcome is that the FDA will limit the label BRCA patients--or at least have less promising results outside BRCA."
CLVS,CLVS:UW,BBG001S2DKJ3,A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision,2017-08-08 18:36:57 +0000,https://finance.yahoo.com/news/biotech-binary-event-playbook-play-183657435.html?.tsrc=rss,Morgan Stanley said in a note Tuesday it would be buyers of Clovis Oncology Inc (NASDAQ: CLVS ) and TESARO Inc (NASDAQ: TSRO ) ahead of the Lynparza label decision. AstraZeneca plc (ADR) (NYSE: AZN )'s ...
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : August 4, 2017",2017-08-04 13:52:54 +0000,http://finance.yahoo.com/r/88fcb168-b555-3f22-b83a-e20de049c51f/clovis-oncology-inc-breached-its-50-day-moving-average-in-a-bearish-manner-clvs-us-august-4-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Clovis Oncology, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses",2017-08-03 16:05:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M_HqQX5lLzA/clovis-clvs-q2-loss-wider-than-expected-rubraca-impresses-cm826555,Clovis Oncology Inc CLVS reported second quarter 2017 loss of 1 29 per share which was narrower than the year ago loss of 2 07 per share The reported loss was however wider than the Zacks Consensus Estimate of a loss of 1 27 Clovis PARP inhibitor Rubraca rucaparib
CLVS,CLVS:UW,BBG001S2DKJ3,"One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?",2017-08-03 15:47:00 +0000,http://finance.yahoo.com/r/c2059ca9-0af8-36e0-9d82-03cfde3c3c45/clovis-oncology-is-selling-off-in-a-bad-way-is-it-time-to-buy.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,One of the hottest biotech stocks of the last month is selling off.
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses",2017-08-03 13:57:01 +0000,https://finance.yahoo.com/news/clovis-clvs-q2-loss-wider-135701017.html?.tsrc=rss,Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca&apos;s label expansion.
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis reports 2Q loss,2017-08-03 02:57:06 +0000,https://finance.yahoo.com/news/clovis-reports-2q-loss-230108529.html?.tsrc=rss,"On a per-share basis, the Boulder, Colorado-based company said it had a loss of $3.88. Losses, adjusted for non-recurring costs, came to $1.29 per share. The results fell short of Wall Street expectations. ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Second Quarter 2017 Operating Results,2017-08-02 20:05:00 +0000,https://finance.yahoo.com/news/clovis-oncology-announces-second-quarter-200500830.html?.tsrc=rss,"Clovis Oncology, Inc. reported financial results for the quarter ended June 30, 2017, and provided an update on the Company’s clinical development programs and regulatory outlook for the remainder of 2017."
CLVS,CLVS:UW,BBG001S2DKJ3,"Investor Network: Clovis Oncology, Inc. to Host Earnings Call",2017-08-02 14:50:00 +0000,https://finance.yahoo.com/news/investor-network-clovis-oncology-inc-145000073.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 2, 2017 / Clovis Oncology, Inc. (NASDAQ: CLVS ) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, August 2, 2017 at 4:30 PM ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Tumbled 13.5% Today,2017-07-31 22:55:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eCqBA0PT3zY/why-clovis-oncology-tumbled-135-today-cm824587,What happened After disclosing that it s entered into a pact with Bristol Myers Squibb NYSE BMY 160 on its cancer fighting drug Rubraca shares in Clovis Oncology NASDAQ CLVS lost 13 5 of their value Monday So what While teaming up with biopharma
CLVS,CLVS:UW,BBG001S2DKJ3,"Gainers & Losers Of July 31: SBBP, AKCA, ACRX, ICPT, ZYNE...",2017-07-31 22:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DnLgQw23eVk/gainers--losers-of-july-31-sbbp-akca-acrx-icpt-zyne-20170731-01572,"Gainers & Losers Of July 31: SBBP, AKCA, ACRX, ICPT, ZYNE..."
CLVS,CLVS:UW,BBG001S2DKJ3,"Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today",2017-07-31 21:55:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pfViNAWAa9A/why-clovis-oncology-gulfport-energy-and-hertz-global-holdings-slumped-today-cm824558,The stock market saw a lot of indecision on Monday as major benchmarks moved in different directions The Nasdaq Composite was weaker than most of its peers but the Dow Jones Industrials jumped to another record high and made investors start thinking about the rapidly
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Tumbled 13.5% Today,2017-07-31 20:51:00 +0000,http://finance.yahoo.com/r/d99f0825-7c5f-38dd-a674-c2b5764f1e81/why-clovis-oncology-tumbled-135-today.aspx?yptr=yahoo&.tsrc=rss,News of a collaboration with Bristol-Myers Squibb dashed some of investor&apos;s hopes that Clovis Oncology could get acquired.
CLVS,CLVS:UW,BBG001S2DKJ3,"Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today",2017-07-31 20:30:00 +0000,http://finance.yahoo.com/r/f35c4809-a195-3d7b-9fe5-66ef822e4c03/why-clovis-oncology-gulfport-energy-and-hertz-glob.aspx?yptr=yahoo&.tsrc=rss,These stocks fell to start the week. Find out why.
CLVS,CLVS:UW,BBG001S2DKJ3,"Why Clovis, Regeneron Are Leading A Biotech Deluge Today",2017-07-31 20:11:39 +0000,http://finance.yahoo.com/r/aec2deb0-3e6d-32d5-801a-9b12278142a8/why-clovis-regeneron-are-leading-a-biotech-deluge-today?src=A00220&yptr=yahoo&.tsrc=rss,Clovis and Regeneron were among some of the biggest biotech stock losers on news related to clinical partnerships.
CLVS,CLVS:UW,BBG001S2DKJ3,"Monday's ETF Movers: IAT, XBI",2017-07-31 18:54:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-v6wD046-9I/mondays-etf-movers-iat-xbi-cm824433,In trading on Monday the iShares U S Regional Banks ETF IAT is outperforming other ETFs up about 1 1 on the day Components of that ETF showing particular strength include shares of M amp T Bank MTB up about 2 1 and shares of Suntrust Banks STI up about 2 on the
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Sell-Off May Be Overdone,2017-07-31 17:45:00 +0000,http://finance.yahoo.com/r/7757bc4b-9fb9-392f-b6d2-b6e6177df909/clovis-pops-on-bristol-myers-partnership-intercept-dives-on-weak-earnings-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31."
CLVS,CLVS:UW,BBG001S2DKJ3,"Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why",2017-07-31 16:10:00 +0000,http://finance.yahoo.com/r/e775e208-6564-34d4-8cac-1d04356e357d/monday-s-worst-performing-stocks-disca-clvs-htz.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Several stocks spent Monday's trading session in the red, and here's why."
CLVS,CLVS:UW,BBG001S2DKJ3,Today's Research Reports on Trending Tickers: Clovis Oncology Inc. and Intercept Pharmaceuticals Inc.,2017-07-31 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000958.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 31, 2017 / U.S. markets were dragged down by shares of Amazon.com Friday after the online retailer posted earnings that fell short of expectations. The S&P 500 Index fell ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Bristol-Myers and Clovis will partner for cancer combination trials,2017-07-31 11:10:39 +0000,http://finance.yahoo.com/r/63f9101f-bf39-3719-882b-852b2c7668bd/Story.aspx?guid=7485744B-0807-4306-942D-7982FBC80127&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb Co. and Clovis Oncology Inc. plan to work together to test a combination of Bristol-Myers' drug Opdivo and Clovis' drug Rubraca in cancer clinical trials. Shares of Clovis were up ...
CLVS,CLVS:UW,BBG001S2DKJ3,Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types,2017-07-31 10:59:00 +0000,https://finance.yahoo.com/news/bristol-myers-squibb-clovis-oncology-105900413.html?.tsrc=rss,"Bristol-Myers Squibb Company and Clovis Oncology, Inc. announced the companies have entered into a clinical collaboration agreement to evaluate the combina"
CLVS,CLVS:UW,BBG001S2DKJ3,What's in the Cards for Merrimack (MACK) in Q2 Earnings?,2017-07-28 16:58:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nUGUmB-x9Ws/whats-in-the-cards-for-merrimack-mack-in-q2-earnings-cm823348,Merrimack Pharmaceuticals Inc MACK is expected to report second quarter 2017 results around Aug 3 Last quarter Merrimack missed bottom line expectations by 214 29 Merrimack s share price has decreased 67 4 year to date against the industry s gain of 10 Let s see how things
CLVS,CLVS:UW,BBG001S2DKJ3,What's in the Cards for Aerie (AERI) This Earnings Season?,2017-07-27 20:57:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3x3f2pyEOnQ/whats-in-the-cards-for-aerie-aeri-this-earnings-season-cm822823,Aerie Pharmaceuticals Inc AERI is scheduled to second quarter 2017 results on Aug 1 Last quarter the company missed expectations by 2 70 In fact Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected loss in the four
CLVS,CLVS:UW,BBG001S2DKJ3,How AstraZeneca Failed Not Once — But Twice — In Cancer Drugs,2017-07-27 20:14:51 +0000,http://finance.yahoo.com/r/bc2ff34b-a2f5-38ce-bc20-c8be2ee61a63/how-astrazeneca-failed-not-once-but-twice-in-cancer-drugs?src=A00220&yptr=yahoo&.tsrc=rss,AstraZeneca not only failed in a lung cancer trial but its partnership with Dow&apos;s Merck appears to be an admission of defeat.
CLVS,CLVS:UW,BBG001S2DKJ3,Can BioMarin (BMRN) Keep the Earnings Streak Alive in Q2?,2017-07-27 15:04:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hPxLMZHV4EQ/can-biomarin-bmrn-keep-the-earnings-streak-alive-in-q2-cm822387,We expect BioMarin Pharmaceutical Inc BMRN to beat expectations when it reports second quarter 2017 results on Aug 2 after the market closes BioMarin delivered a positive earnings surprise of 110 in the last quarter BioMarin s shares are up 7 7 so far this year This
CLVS,CLVS:UW,BBG001S2DKJ3,What's in Store for Endocyte (ECYT) this Earnings Season?,2017-07-26 16:59:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ccka11cqmEI/whats-in-store-for-endocyte-ecyt-this-earnings-season-cm821804,Endocyte Inc ECYT is expected to report second quarter 2017 results on Aug 3 The company has a mixed track record having beaten the Zacks Consensus Estimate in three of the trailing four quarters and missing the same in the remaining quarter Overall the company delivered an
CLVS,CLVS:UW,BBG001S2DKJ3,AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?,2017-07-26 16:04:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/We_3LvdX5JU/aveo-pharmaceuticals-aveo-q2-earnings-whats-in-store-cm821682,AVEO Pharmaceuticals Inc AVEO is expected to report second quarter 2017 results next week In the last reported quarter AVEO delivered a positive surprise of 7 69 Let s see how things are shaping up for this quarter AVEO s share price movement shows that the stock has
CLVS,CLVS:UW,BBG001S2DKJ3,"XBI, CLVS, EXEL, ALXN: ETF Outflow Alert",2017-07-26 15:57:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QwxLkjjKPJc/xbi-clvs-exel-alxn-etf-outflow-alert-cm821649,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 112 8 million dollar outflow that s a 2 8 decrease week over week from 50 050 000
CLVS,CLVS:UW,BBG001S2DKJ3,What's in the Cards for Merck KGaA (MKGAF) in Q2 Earnings?,2017-07-24 17:09:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1hsDxTLVVvI/whats-in-the-cards-for-merck-kgaa-mkgaf-in-q2-earnings-cm820316,Merck KGaA MKGAF is scheduled to report second quarter 2017 earnings results on Aug 3 Merck KGaA s share price has increased 10 year to date while the industry gained 6 3 The company reports results under three business sectors Healthcare Life Science and Performance
CLVS,CLVS:UW,BBG001S2DKJ3,3 Stocks at 52-Week Highs Still Worth Buying,2017-07-18 15:05:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dz0ZLk-cj_o/3-stocks-at-52-week-highs-still-worth-buying-cm817417,Stocks near or at their 52 week highs are rarely compelling buys These highfliers after all generally tend to take a breather upon reaching new heights or worse still reverse course With this theme in mind we asked three of our investors which stocks they think might be
CLVS,CLVS:UW,BBG001S2DKJ3,3 Stocks at 52-Week Highs Still Worth Buying,2017-07-18 13:05:00 +0000,http://finance.yahoo.com/r/4924340e-58d7-3f25-ba58-126b2151dc34/3-stocks-at-52-week-highs-still-worth-buying.aspx?yptr=yahoo&.tsrc=rss,These three top stocks still have room to grow.
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion,2017-07-13 23:47:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xt4N_QITDBw/clovis-clvs-focuses-on-rubraca-launch-and-label-expansion-cm815926,We issued an updated research report on Boulder CO based Clovis Oncology Inc CLVS on Jul 12 Clovis got a huge boost in Dec 2016 when the FDA granted accelerated approval to its PARP inhibitor Rubraca rucaparib for the treatment of advanced ovarian cancer two months earlier than
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion,2017-07-13 21:37:09 +0000,https://finance.yahoo.com/news/clovis-clvs-focuses-rubraca-launch-213709873.html?.tsrc=rss,"We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12."
CLVS,CLVS:UW,BBG001S2DKJ3,"XBI, CLVS, EXEL, ALXN: Large Inflows Detected at ETF",2017-07-13 16:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n377MjGb2Vs/xbi-clvs-exel-alxn-large-inflows-detected-at-etf-cm815708,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 196 6 million dollar inflow that s a 5 4 increase week over week in outstanding
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why Clovis Oncology Inc. Jumped 70% in June,2017-07-07 13:48:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RkMPOGb_6h0/heres-why-clovis-oncology-inc-jumped-70-in-june-cm812864,What happened Clovis Oncology Inc NASDAQ CLVS stock soared 69 6 in June according to data from S amp P Global Market Intelligence Clinical trial results showed the company s lead drug Rubraca provided a significant long term survival benefit So what Late last
CLVS,CLVS:UW,BBG001S2DKJ3,Here&apos;s Why Clovis Oncology Inc. Jumped 70% in June,2017-07-07 11:43:00 +0000,http://finance.yahoo.com/r/9eadb703-6332-32cb-a892-4e4ece57abb8/heres-why-clovis-oncology-inc-jumped-70-in-june.aspx?yptr=yahoo&.tsrc=rss,The company&apos;s lead drug produced long-term results that should cement its position in the ovarian-cancer space.
CLVS,CLVS:UW,BBG001S2DKJ3,"Noteworthy ETF Outflows: XBI, CLVS, EXEL, ALXN",2017-07-05 16:45:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pDZmOw0HFkE/noteworthy-etf-outflows-xbi-clvs-exel-alxn-cm811897,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 155 9 million dollar outflow that s a 4 2 decrease week over week from 48 000 000
CLVS,CLVS:UW,BBG001S2DKJ3,This Rebounding Pharma Stock May Launch Another Breakout Move,2017-06-30 20:14:53 +0000,http://finance.yahoo.com/r/2bc05d5c-de3c-3061-8fe5-9a918d7fbba7/this-rebounding-pharma-stock-may-launch-another-breakout-move?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Jazz Pharmaceuticals shows improving technical performance.
CLVS,CLVS:UW,BBG001S2DKJ3,"3 Stocks That Turned $8,000 Into at Least $25,600 in Just One Year",2017-06-29 14:41:00 +0000,http://finance.yahoo.com/r/d4d80f46-774d-3659-9a78-f979df031cc8/3-stocks-that-turned-8000-into-at-least-25600-in-j.aspx?yptr=yahoo&.tsrc=rss,"Long-term buy-and-hold investing works best, but short-term gains are nice when they happen."
CLVS,CLVS:UW,BBG001S2DKJ3,Is It Too Late to Buy Clovis Oncology Stock?,2017-06-27 19:43:00 +0000,http://finance.yahoo.com/r/c586dfa2-18e7-3f1b-b9fc-43eca6049890/is-it-too-late-to-buy-clovis-oncology-stock.aspx?yptr=yahoo&.tsrc=rss,Clovis Oncology is one of the hottest biotech stocks on the market. But is it likely to cool off now?
CLVS,CLVS:UW,BBG001S2DKJ3,SPDR S&P Biotech ETF Experiences Big Inflow,2017-06-27 16:51:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MZr0g5PMcjY/spdr-sp-biotech-etf-experiences-big-inflow-cm808861,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 264 2 million dollar inflow that s a 7 4 increase week over week in outstanding
CLVS,CLVS:UW,BBG001S2DKJ3,"Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?",2017-06-27 11:02:00 +0000,http://finance.yahoo.com/r/1ebec010-2c7c-3f86-a7f8-8c0c17597b09/will-abbvie-outsmart-biosimilars-and-can-clovis-wi.aspx?yptr=yahoo&.tsrc=rss,"A look under the hood at AbbVie Inc., how Novartis is prepping to fight Regeneron, and can Clovis capture the lead in the PARP race?"
CLVS,CLVS:UW,BBG001S2DKJ3,Seattle Genetics: A Disappointing Study…Or Was It?,2017-06-26 18:52:00 +0000,http://finance.yahoo.com/r/6af3866f-8299-3e70-b1cc-b4d07210c8ee/seattle-genetics-a-disappointing-studyor-was-it-1498503146?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress.  The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint.  Altogether, lots of uncertainty whether these data could support a robust commercial adoption."
CLVS,CLVS:UW,BBG001S2DKJ3,3 Growth Stocks for Bright Investors,2017-06-23 19:40:00 +0000,http://finance.yahoo.com/r/41654bf1-dede-39cd-b5c4-53f74c0cfe0d/3-growth-stocks-for-bright-investors-2.aspx?yptr=yahoo&.tsrc=rss,For bright investors in search of some new ideas here are three stocks worth a good look.
CLVS,CLVS:UW,BBG001S2DKJ3,Healthcare ETF (IYH) Hits New 52-Week High,2017-06-23 13:00:01 +0000,https://finance.yahoo.com/news/healthcare-etf-iyh-hits-52-130001504.html?.tsrc=rss,This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology commencing $250 million stock offering,2017-06-22 17:05:07 +0000,http://finance.yahoo.com/r/36dc6483-268a-34a2-8b42-42beb3b2e210/clovis-oncologycommencing-250-million-stock.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"One day after announcing good results of a trial of its ovarian cancer drug rucaparib, Clovis Oncology Inc. said it's commencing a $250 million public offering of its stock.  Clovis will use the money for sales and marketing of its drug rucaparib, both in the United States and, if approved by the European Medicines Agency, in Europe, as well as to fund the compay's drug development programs, general and administrative expenses, and possible acquisitions or licensing of of new drug candidates, the Boulder biotech said in a statement.  Reaction to the stock offering is positive enough that the investment banks underwriting it exercised their option to purchase an additional 511,363 shares, Clovis said Thursday."
CLVS,CLVS:UW,BBG001S2DKJ3,5 Reasons Why Biotech ETFs are Soaring,2017-06-22 15:17:03 +0000,https://finance.yahoo.com/news/5-reasons-why-biotech-etfs-151703504.html?.tsrc=rss,Reasons that propelled the biotech space and the related ETFs higher.
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. (CLVS) Worth a Look: Stock Jumps 6.3%",2017-06-22 12:43:12 +0000,https://finance.yahoo.com/news/clovis-oncology-inc-clvs-worth-124312935.html?.tsrc=rss,"Clovis Oncology, Inc. (CLVS)) shares rose over 6% on solid volume after the company&apos;s announcement regarding the pricing of its shares"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock,2017-06-21 22:56:00 +0000,https://finance.yahoo.com/news/clovis-oncology-announces-exercise-full-225600934.html?.tsrc=rss,"Clovis Oncology, Inc. announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares."
CLVS,CLVS:UW,BBG001S2DKJ3,4 Stocks & ETFs to Buy on Clovis&apos; Positive Drug Data,2017-06-21 16:42:04 +0000,https://finance.yahoo.com/news/4-stocks-etfs-buy-clovis-164204661.html?.tsrc=rss,Clovis Oncology clinical trial data has given a boost to the biotech sector and put these stocks and ETFs in focus.
CLVS,CLVS:UW,BBG001S2DKJ3,"Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More",2017-06-21 13:35:01 +0000,https://finance.yahoo.com/news/small-cancer-biotech-space-focus-133501277.html?.tsrc=rss,The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock,2017-06-20 23:06:00 +0000,https://finance.yahoo.com/news/clovis-oncology-announces-upsizing-pricing-230600932.html?.tsrc=rss,"Clovis Oncology, Inc. announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.00 per share, before underwriting discounts and commissions."
CLVS,CLVS:UW,BBG001S2DKJ3,These Biotechs Are Leading The Sector To A 3-Month High Today,2017-06-20 20:43:03 +0000,http://finance.yahoo.com/r/bb019aaa-2994-3817-b22d-d3c911ebc678/these-biotechs-are-leading-the-sector-to-a-3-month-high-today?src=A00220&yptr=yahoo&.tsrc=rss,"Shares of cancer-focused biotechs Bluebird, Clovis and Kite popped Tuesday, leading a sectorwide boom to a three-month high."
CLVS,CLVS:UW,BBG001S2DKJ3,Could Tesaro Overcome Clovis&apos; Lead On Combos With Merck & Co.?,2017-06-20 20:15:34 +0000,http://finance.yahoo.com/r/70afb7df-c293-387c-8509-71c79add6a57/could-tesaro-scuttle-clovis-lead-on-combos-with-merck-bristol-roche?src=A00220&yptr=yahoo&.tsrc=rss,"Tesaro&apos;s Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche."
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech Stocks To Watch And Pharma Industry News,2017-06-20 18:39:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study,2017-06-20 17:21:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sMAgauodimk/clovis-up-nearly-50-on-solid-data-from-ovarian-cancer-study-cm805792,Clovis Oncology Inc CLVS shares soared nearly 50 on Monday after it announced positive top line results from a pivotal late stage maintenance study on its newly launched ovarian cancer drug Rubraca Promising progression free survival PFS and safety results from the pivotal
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech ETFs: Still Riding High,2017-06-20 16:21:00 +0000,http://finance.yahoo.com/r/d2498f70-dd3c-3481-9e56-9cdf22c2e396/biotech-etfs-still-riding-high-1497975722?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The biotechnology-stock rally continues. The SPDR S&P Biotech (XBI) and the iShares Nasdaq Biotechnology (IBB), among the highest-flying exchange-traded funds yesterday, both hit their 52-week highs on ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study,2017-06-20 15:10:03 +0000,https://finance.yahoo.com/news/clovis-nearly-50-solid-data-151003305.html?.tsrc=rss,"Clovis Oncology, Inc. (CLVS) shares soared nearly 50% on Monday after it announced positive top-line results from a pivotal late-stage maintenance study on its newly launched ovarian cancer drug, Rubraca."
CLVS,CLVS:UW,BBG001S2DKJ3,CLVS Crosses Above Average Analyst Target,2017-06-20 14:19:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DNnwpY28ntw/clvs-crosses-above-average-analyst-target-cm805516,In recent trading shares of Clovis Oncology Inc Symbol CLVS have crossed above the average analyst 12 month target price of 70 57 changing hands for 87 88 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
CLVS,CLVS:UW,BBG001S2DKJ3,"Biotech Movers: AveXis, Clovis, Epizyme",2017-06-20 13:33:00 +0000,http://finance.yahoo.com/r/b227c02e-9b38-3d18-8cfb-acbc7218c425/biotech-movers-avexis-clovis-epizyme.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"AveXis, Clovis Oncology and Epizyme were among the biotech stock movers in premarket trading on June 20."
CLVS,CLVS:UW,BBG001S2DKJ3,Today's Research Reports on Stocks to Watch: Clovis Oncology and Valeant Pharmaceuticals,2017-06-20 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000682.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / June 20, 2017 / Clovis Oncology soars to a share price it hasn't seen in almost two years after revealing positive trial results for its ovarian cancer drug Rubraca. Shares ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Why These Biotech Stocks Are Gaining,2017-06-20 10:00:00 +0000,http://finance.yahoo.com/r/65bae733-4212-3bc8-9b24-2ec211a0ef9f/why-these-biotech-stocks-are-gaining?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Biotech stocks soared on June 19, easily the best performing group in the market."
CLVS,CLVS:UW,BBG001S2DKJ3,[$$] The Dark Side of Good News in Biotech,2017-06-20 04:37:23 +0000,http://finance.yahoo.com/r/a24b1eb1-bc4f-3f7a-8d16-da32b332a835/the-dark-side-of-good-news-in-biotech-1497886898?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Deal making is a staple of the biotech industry, but betting on mergers and acquisitions is much harder than it looks for investors."
CLVS,CLVS:UW,BBG001S2DKJ3,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade",2017-06-20 02:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mVef7veM52A/amgns-xgeva-to-face-fda-in-feb-double-treat-for-lpcn-sgen-drops-cascade-20170620-00069,"AMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade"
CLVS,CLVS:UW,BBG001S2DKJ3,Here's what's behind the biotech breakout,2017-06-19 21:28:00 +0000,https://finance.yahoo.com/video/heres-whats-behind-biotech-breakout-212800606.html?.tsrc=rss,CNBC's Meg Tirrell reports on the biotech surge from Clovis and Tesaro as they compete in the same medical space.
CLVS,CLVS:UW,BBG001S2DKJ3,Why This Cancer Drug Specialist Is Up 50% Today,2017-06-19 20:55:24 +0000,http://finance.yahoo.com/r/1a4e7148-9c5f-3d53-bde7-2c714b330b1e/clovis-soars-on-ovarian-cancer-drug-study-rivals-fall?src=A00220&yptr=yahoo&.tsrc=rss,Clovis Oncology soared early Monday on data suggesting a much-wider use for its ovarian cancer drug Rubraca. Shares of Tesaro tumbled.
CLVS,CLVS:UW,BBG001S2DKJ3,"Gainers & Losers Of June 19: ARNA, NVDQ, CLVS, RWLK, CLSN...",2017-06-19 20:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N1eoC5VGWKs/gainers--losers-of-june-19-arna-nvdq-clvs-rwlk-clsn-20170619-01233,"Gainers & Losers Of June 19: ARNA, NVDQ, CLVS, RWLK, CLSN..."
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech Flew Nearly 50% On Strong Trial — But Is Its Drug Better?,2017-06-19 20:38:36 +0000,http://finance.yahoo.com/r/2382afb2-991a-3b4f-8957-dba27d6fe41e/this-biotech-flew-50-on-a-strong-trial-but-is-its-drug-really-better?src=A00220&yptr=yahoo&.tsrc=rss,"Clovis&apos; Rubraca isn&apos;t wildly different from Tesaro&apos;s Zejula in ovarian cancer, analysts said Monday."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology's Rubraca Notches Key Trial Win,2017-06-19 20:20:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CMckR_nvcuI/clovis-oncologys-rubraca-notches-key-trial-win-cm805317,Clovis Oncology s NASDAQ CLVS Rubraca is already approved for use in ovarian cancer patients who have seen their disease return following two or more chemotherapies Soon the Food and Drug Administration may clear its use in patients following one or more treatments
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Inc (CLVS) Stock Just Shot 50% Higher,2017-06-19 20:19:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75-bCtnN78s/why-clovis-oncology-inc-clvs-stock-just-shot-50-higher-cm805342,InvestorPlace Stock Market News Stock Advice amp Trading Tips Clovis Oncology Inc NASDAQ CLVS reported positive data from a late stage trial for its ovarian cancer drug Rubraca While Rubraca already has FDA approval CLVS stock responded with glee at
CLVS,CLVS:UW,BBG001S2DKJ3,"As Clovis Oncology Soars, This Big Pharma Stock Clears New Buy Zone",2017-06-19 20:15:58 +0000,http://finance.yahoo.com/r/81937626-2360-30fc-8b38-09990c67b785/as-clovis-oncology-soars-this-big-pharma-stock-clears-new-buy-zone?src=A00220&yptr=yahoo&.tsrc=rss,"AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to launch $250 mln stock offering,2017-06-19 20:12:30 +0000,http://finance.yahoo.com/r/50404abc-aba1-30ec-af8b-44eb9d213434/Story.aspx?guid=B24B5EB3-913B-4B5E-988E-7A041341353B&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Clovis Oncology Inc. said on Monday it plans to launch a $250 million stock offering. The announcement follows a 46.5% surge in Clovis Oncology shares after the company released positive late-stage trial ...
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Proposed Offering of Common Stock,2017-06-19 20:01:00 +0000,https://finance.yahoo.com/news/clovis-oncology-announces-proposed-offering-200100578.html?.tsrc=rss,"Clovis Oncology, Inc. announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million."
CLVS,CLVS:UW,BBG001S2DKJ3,"Health Care Sector Update for 06/19/2017: CLVS,NVDQ,SYK,SGEN",2017-06-19 19:19:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EU3Eo6IYs54/health-care-sector-update-for-06192017-clvsnvdqsyksgen-cm805297,Top Health Care StocksTop Health Care Stocks JNJ 0 36 JNJ 0 36 PFE 0 82 PFE 0 82 ABT 1 53 ABT 1 53 MRK 1 27 MRK 1 27 AMGN 1 43 AMGN 1 43 Health care stocks were putting up strong gains to start the new week with the NYSE Health Care Index adding more than 0 8 while shares of
CLVS,CLVS:UW,BBG001S2DKJ3,"US STOCKS-Wall St at record highs on technology, health stocks strength",2017-06-19 19:02:55 +0000,https://finance.yahoo.com/news/us-stocks-wall-st-record-190255181.html?.tsrc=rss,"U.S. stocks rose on Monday,  with the S&P 500 and the Dow Jones Industrial Average hitting  record highs helped by a technology sector rebound and strength  in healthcare and financial stocks.  Nasdaq's biotechnology index rose 2.5 percent and was  on track for its biggest one-day gain since February helped by  stocks including Biogen Inc and Clovis Oncology  while the S&P's healthcare index hit a record  high."
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech stocks are having their best day since February,2017-06-19 18:28:24 +0000,http://finance.yahoo.com/r/eb1f5b61-b3fc-3631-8e65-433ccdb64983/104538030?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104538030&yptr=yahoo&.tsrc=rss,"The SPDR Biotech ETF is up 3 percent on Monday, boosted by Clovis Oncology shares surging 46 percent."
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech stocks are having their best day since February,2017-06-19 18:28:24 +0000,https://finance.yahoo.com/news/biotech-stocks-having-best-day-182824309.html?.tsrc=rss,"The SPDR Biotech ETF is up 3 percent on Monday, boosted by Clovis Oncology shares surging 46 percent."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology&apos;s Rubraca Notches Key Trial Win,2017-06-19 18:21:00 +0000,http://finance.yahoo.com/r/64eb0bd7-5e74-32ec-975e-19b4574fc6f6/clovis-oncologys-rubraca-notches-key-trial-win.aspx?yptr=yahoo&.tsrc=rss,The addressable market for Rubraca could be about to get bigger.
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why Clovis Oncology (CLVS) Stock Skyrocketed Today,2017-06-19 18:19:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rJoOKWhSuts/heres-why-clovis-oncology-clvs-stock-skyrocketed-today-cm805243,Shares of Clovis Oncology CLVS opened more than 40 higher on Monday morning after the company announced positive results in a late stage trial involving its Rubraca therapy an outcome that could help widen the use of the drug and give Clovis a competitive edge Clovis said that Rubraca
CLVS,CLVS:UW,BBG001S2DKJ3,"Monday's ETF Movers: XBI, GDXJ",2017-06-19 18:19:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LBDFnBck-Qo/mondays-etf-movers-xbi-gdxj-cm805242,In trading on Monday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 3 8 on the day Components of that ETF showing particular strength include shares of Arena Pharmaceuticals ARNA up about 871 8 and shares of Clovis Oncology CLVS up about 47 2 on
CLVS,CLVS:UW,BBG001S2DKJ3,Why Tesaro Inc. Stock Briefly Dipped Today,2017-06-19 17:22:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cLdXjmUaOsM/why-tesaro-inc-stock-briefly-dipped-today-cm805195,What happened Tesaro NASDAQ TSRO a mid cap oncology company saw its shares dip by as much as 10 6 in early morning trading today on more than double the average volume Although the company s shares have since rebounded and are only down by 2 95 as of 10 30 a m
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro: Is The Selloff Overdone?,2017-06-19 16:37:00 +0000,http://finance.yahoo.com/r/e35002e9-bbf3-36b1-8499-a2f8fe811b06/tesaro-is-the-selloff-overdone-1497890262?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The initial panic that surrounded shares of Tesaro (TSRO) this morning appears to have eased back quite a bit.  Tesaro is one of three leaders in the market for so-called PARP inhibitors, a new class of cancer drug.  Earlier today, rival Clovis Oncology (CLVS) released data for its drug Rubraca that fueled worries about Tesaro’s hold on the market."
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Stock Is Soaring Today,2017-06-19 16:23:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2Fgc1aURadM/why-clovis-oncology-stock-is-soaring-today-cm805104,What happened Shares of Clovis Oncology NASDAQ CLVS opened up trading today 46 higher than they were at Friday s close The drugmaker s stock is surging as a result of the successful Phase 3 readout for its 160 BRCA mutant ovarian cancer drug Rubraca in a confirmatory study
CLVS,CLVS:UW,BBG001S2DKJ3,Dow And S&P 500 Climb To New Record Closing Highs - U.S. Commentary,2017-06-19 16:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DBMjiMPOTXs/dow-and-sp-500-climb-to-new-record-closing-highs--us-commentary-20170619-01097,Dow And S&P 500 Climb To New Record Closing Highs - U.S. Commentary
CLVS,CLVS:UW,BBG001S2DKJ3,Why Cancer Biotech Clovis Oncology’s Stock Is Soaring,2017-06-19 15:48:06 +0000,https://finance.yahoo.com/news/why-cancer-biotech-clovis-oncology-154806507.html?.tsrc=rss,Impressive ovarian cancer drug data could make life hard for its rivals.
CLVS,CLVS:UW,BBG001S2DKJ3,Here&apos;s Why Clovis Oncology (CLVS) Stock Skyrocketed Today,2017-06-19 15:48:03 +0000,https://finance.yahoo.com/news/apos-why-clovis-oncology-clvs-154803813.html?.tsrc=rss,Shares of Clovis Oncology (CLVS) opened more than 40% higher on Monday morning after the company announced positive results in a late-stage trial involving its Rubraca therapy--an outcome that could help widen the use of the drug and give Clovis a competitive edge.
CLVS,CLVS:UW,BBG001S2DKJ3,Why Tesaro Inc. Stock Briefly Dipped Today,2017-06-19 15:45:00 +0000,http://finance.yahoo.com/r/097c109c-4019-3e58-8629-ad97dcfe7edd/why-tesaro-inc-stock-briefly-dipped-today.aspx?yptr=yahoo&.tsrc=rss,An emerging competitive threat caused Tesaro&apos;s stock to briefly dip today.
CLVS,CLVS:UW,BBG001S2DKJ3,[$$] The Dark Side of Good News in Biotech,2017-06-19 15:44:41 +0000,http://finance.yahoo.com/r/a24b1eb1-bc4f-3f7a-8d16-da32b332a835/the-dark-side-of-good-news-in-biotech-1497886898?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Deal making is a staple of the biotech industry, but betting on mergers and acquisitions is much harder than it looks for investors."
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Stock Is Soaring Today,2017-06-19 15:00:00 +0000,http://finance.yahoo.com/r/caf2574f-6ff7-3e0d-983d-6b47db77c5d3/why-clovis-oncology-stock-is-soaring-today.aspx?yptr=yahoo&.tsrc=rss,"The drugmaker&apos;s ovarian cancer treatment, Rubraca, hit another major clinical milestone."
CLVS,CLVS:UW,BBG001S2DKJ3,"Analysts Weigh in on Two Skyrocketing Stocks: Novadaq Technologies Inc. (NVDQ), Clovis Oncology Inc (CLVS)",2017-06-19 14:56:39 +0000,https://finance.yahoo.com/news/analysts-weigh-two-skyrocketing-stocks-145639841.html?.tsrc=rss,"Novadaq Technologies Inc. (NASDAQ:NVDQ) shares are skyrocketing 95% to $11.70, following the news that  Stryker (NYSE:SYK) had reached a definitive agreement to acquire all the issued and outstanding shares in Novadaq for $11.75 per share, or $701 million, a 96% premium based on NOVADAQ’s share price at the close of Friday’s trading.  Stryker is the logical acquirer for Novadaq since it sells video equipment into operating rooms and has its own fluorescence option that lacks the Novadaq’s technology.  Lavin reiterates a Neutral rating on Novadaq shares, while no price target was provided."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis surges on positive cancer-drug data,2017-06-19 14:37:00 +0000,https://finance.yahoo.com/video/clovis-surges-positive-cancer-drug-143700598.html?.tsrc=rss,CNBC's Meg Tirrell reports the latest biotech and health care news including Clovis Oncology's new ovarian cancer drug study sending shares up.
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis's ovarian cancer drug set for label expansion, shares soar",2017-06-19 14:36:08 +0000,https://finance.yahoo.com/news/clovis-oncologys-cancer-drug-rubraca-083526278.html?.tsrc=rss,"Clovis Oncology Inc said on  Monday late-stage data on its already-approved ovarian cancer  drug showed that the treatment could benefit four times as many  patients, sending shares of the U.S. biotech soaring 50 percent.  Clovis's late-stage trial was designed to move its drug,  Rubraca, up to a second-line treatment and later, a maintenance  treatment.  Maintenance therapy immediately follows initial  treatment to keep patients cancer-free if they go into  remission."
CLVS,CLVS:UW,BBG001S2DKJ3,What's Next For Clovis Oncology?,2017-06-19 14:36:00 +0000,http://finance.yahoo.com/r/9cb50b1e-9644-3662-a684-b88b3e18a203/whats-next-for-clovis-oncology-1497882976?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Talk about good timing. Credit Suisse sweetened its outlook for Clovis Oncology (CLVS) on Friday, maintaining an Outperform rating and lifting its price target from $74 to $88 a share. Analyst Alethia ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Wall Street Sees Higher Open as Tech Sector Continues Recovery,2017-06-19 13:59:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GImaIjnFImo/wall-street-sees-higher-open-as-tech-sector-continues-recovery-cm804981,U S stocks were set for a higher open Monday as stocks in the technology sector continued to make a recovery from a days long selloff U S stocks were set for a higher open Monday as stocks in the technology sector continued to make a recovery from a days long selloff Oil prices rebounded
CLVS,CLVS:UW,BBG001S2DKJ3,Story Stocks from Briefing.com,2017-06-19 13:33:14 +0000,https://finance.yahoo.com/news/story-stocks-briefing-com-175403381.html?.tsrc=rss,Story Stocks from Briefing.com
CLVS,CLVS:UW,BBG001S2DKJ3,"Biotech Movers: Clovis, Seattle Genetics, Rigel",2017-06-19 13:08:00 +0000,http://finance.yahoo.com/r/36fd8f41-9c38-3614-8c87-8d503013cdd2/biotech-movers-clovis-seattle-genetics-rigel.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Surges on Clutch Late-Stage Ovarian Cancer Trial,2017-06-19 13:00:14 +0000,https://finance.yahoo.com/news/clovis-oncology-surges-clutch-stage-125814966.html?.tsrc=rss,Clovis Oncology saw its shares make a massive gain early on Monday after the company announced top-line data from its confirmatory Phase 3 trial of its treatment of ovarian cancer.
CLVS,CLVS:UW,BBG001S2DKJ3,US Futures Nudge Higher as Tech Sector Extends Recovery,2017-06-19 12:59:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kbTAHQYPmIc/us-futures-nudge-higher-as-tech-sector-extends-recovery-cm804905,U S stock futures nudged higher on Monday as stocks in the technology sector continued to make a recovery from a days long selloff U S stock futures nudged higher on Monday as stocks in the technology sector continued to make a recovery from a days long selloff Oil prices rebounded from
CLVS,CLVS:UW,BBG001S2DKJ3,"Pre-Market Most Active for Jun 19, 2017 :  AEG, RICE, CLVS, AUY, QQQ, NVDQ, VRX, RIGL, HL, TSRO, KR, JD",2017-06-19 12:59:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JhzwvVCoHcI/pre-market-most-active-for-jun-19-2017-aeg-rice-clvs-auy-qqq-nvdq-vrx-rigl-hl-tsro-kr-jd-cm804906,The NASDAQ 100 Pre Market Indicator is up 32 17 to 5 713 65 The total Pre Market volume is currently 7 766 242 shares traded The following are the most active stocks for the pre market session Aegon NV AEG is 0 03 at 5 06 with 1 120 700 shares traded AEG s
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology stock surges 50% on positive late-stage cancer trial results,2017-06-19 12:51:21 +0000,http://finance.yahoo.com/r/8861663d-9bae-3af7-8365-f39f25aa17f9/Story.aspx?guid=96BF770F-46FE-4367-84EF-8ADB582BB43F&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Clovis Oncology Inc. shares surged 50% in premarket trade Monday after the company said its late-stage trial for a cancer drug met its primary endpoint and a key secondary endpoint. Clovis said it plans ...
CLVS,CLVS:UW,BBG001S2DKJ3,Stocks Hovering In Positive Territory In Mid-Day Trading - U.S. Commentary,2017-06-19 12:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T7_KAR7lvtk/stocks-hovering-in-positive-territory-in-midday-trading--us-commentary-20170619-00879,Stocks Hovering In Positive Territory In Mid-Day Trading - U.S. Commentary
CLVS,CLVS:UW,BBG001S2DKJ3,Cancer Treatment Maker Clovis Skyrockets On Positive Trial Results,2017-06-19 09:43:00 +0000,http://finance.yahoo.com/r/03d2ae91-2faf-3c0c-8582-953c78bc9ac6/cancer-treatment-maker-clovis-skyrockets-on-positive-trial-results?src=A00220&yptr=yahoo&.tsrc=rss,Clovis is surging some 50% on positive trial results for its ovarian cancer treatment.
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Inc. (CLVS) Has Soared To A New High On Phase 3 Study Results,2017-06-19 09:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZZOPZFAkN_4/clovis-oncology-inc-clvs-has-soared-to-a-new-high-on-phase-3-study-results-20170619-00688,Clovis Oncology Inc. (CLVS) Has Soared To A New High On Phase 3 Study Results
CLVS,CLVS:UW,BBG001S2DKJ3,InPlay from Briefing.com,2017-06-19 08:54:37 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
CLVS,CLVS:UW,BBG001S2DKJ3,Stocks May Benefit From Strength Overseas - U.S. Commentary,2017-06-19 08:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tyct4XQAJuQ/stocks-may-benefit-from-strength-overseas--us-commentary-20170619-00555,Stocks May Benefit From Strength Overseas - U.S. Commentary
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology’s Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial,2017-06-19 07:45:00 +0000,https://finance.yahoo.com/news/clovis-oncology-rucaparib-significantly-improved-074500718.html?.tsrc=rss,"Clovis Oncology, Inc. today announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival by investigator review in each of the three populations studied."
CLVS,CLVS:UW,BBG001S2DKJ3,New test may turn AZ's Lynparza into precision drug for prostate cancer,2017-06-18 23:01:00 +0000,https://finance.yahoo.com/news/test-may-turn-azs-lynparza-230100457.html?.tsrc=rss,"Scientists have developed a new  three-in-one blood test that has the potential to turn  AstraZeneca's drug Lynparza into a precision medicine  for prostate cancer.  Lynparza, which is already approved for ovarian and recently  produced good results in breast cancer, is currently in clinical  development against prostate tumours.  Researchers at the Institute of Cancer Research (ICR) in  London said on Monday their new test was able to pick out which  men with advanced disease were likely to benefit from the drug,  while also checking that those taking it were responding."
CLVS,CLVS:UW,BBG001S2DKJ3,"Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?",2017-06-16 20:41:01 +0000,http://finance.yahoo.com/r/9709ede1-9b26-34d9-a31d-dd6edd399ea2/can-astrazeneca-keep-up-as-clovis-tesaro-unveil-blockbuster-drugs?src=A00220&yptr=yahoo&.tsrc=rss,"Clovis and Tesaro could each deliver blockbuster ovarian cancer drugs and grab takeover interest, an analyst said Friday."
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year,2017-06-16 16:10:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-InYC0mN8p4/heres-why-clovis-clvs-stock-is-up-almost-350-in-one-year-cm804391,Shares of Clovis Oncology Inc CLVS continue to witness an upside The uptrend started in the third quarter of 2016 In fact shares of this small biotech company are up a massive 343 7 in the past one year outperforming the 4 3 decrease registered by the Zacks classified Biomed
CLVS,CLVS:UW,BBG001S2DKJ3,Here&apos;s Why Clovis (CLVS) Stock is Up Almost 350% in One Year,2017-06-16 13:55:01 +0000,https://finance.yahoo.com/news/apos-why-clovis-clvs-stock-135501557.html?.tsrc=rss,"Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016."
CLVS,CLVS:UW,BBG001S2DKJ3,"ETFs with exposure to Clovis Oncology, Inc. : June 15, 2017",2017-06-15 17:32:10 +0000,http://finance.yahoo.com/r/95b99c44-5650-3ccc-9b49-e5343c088e99/etfs-with-exposure-to-clovis-oncology-inc-june-15-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Clovis Oncology, Inc. Here are 5 ETFs with the largest exposure to CLVS-US. Comparing the performance and risk of Clovis Oncology, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
<b>(Read more...)</b>"
CLVS,CLVS:UW,BBG001S2DKJ3,"Surging Earnings Estimates Signal Good News for Clovis Oncology, Inc. (CLVS)",2017-06-15 14:11:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A4nSbcbQI6M/surging-earnings-estimates-signal-good-news-for-clovis-oncology-inc-clvs-cm803848,Clovis Oncology Inc CLVS is a Medical Biomedical and Genetics company that could be an interesting play for investors That is because not only does the stock have decent short term momentum but it is seeing solid activity on the earnings estimate revision front as well These
CLVS,CLVS:UW,BBG001S2DKJ3,"Surging Earnings Estimates Signal Good News for Clovis Oncology, Inc. (CLVS)",2017-06-15 12:36:12 +0000,https://finance.yahoo.com/news/surging-earnings-estimates-signal-good-123612253.html?.tsrc=rss,"Surging Earnings Estimates and a favorable Zacks rank Signal Good News for Clovis Oncology, Inc. (CLVS)"
CLVS,CLVS:UW,BBG001S2DKJ3,"Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors",2017-06-14 13:05:00 +0000,https://finance.yahoo.com/news/sienna-biopharmaceuticals-appoints-erle-mast-130500664.html?.tsrc=rss,"WESTLAKE VILLAGE, Calif., June 14, 2017-- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"Biotech Movers: Acceleron, Clovis, Coherus",2017-06-13 13:28:00 +0000,http://finance.yahoo.com/r/f5ee8e75-13a2-3a15-83ff-5785685971f9/biotech-movers-acceleron-clovis-coherus.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Acceleron Pharma, Clovis Oncology and Coherus BioSciences premarket trading on Tuesday."
CLVS,CLVS:UW,BBG001S2DKJ3,"3 Stocks Warren Buffett Can't Buy, but You Can",2017-06-12 15:30:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OK3e7qD4Oxk/3-stocks-warren-buffett-cant-buy-but-you-can-cm802054,Warren Buffett has bought many stocks during his long career As the years have gone by and as Buffett has become wildly successful he s had to be increasingly more selective about which stocks he could buy and which he couldn t He can t buy small companies anymore because the amount
CLVS,CLVS:UW,BBG001S2DKJ3,"3 Stocks Warren Buffett Can&apos;t Buy, but You Can",2017-06-12 13:40:00 +0000,http://finance.yahoo.com/r/d34911a7-ae27-3224-9ec8-8d1ab8e557c0/3-stocks-warren-buffett-cant-buy-but-you-can-2.aspx?yptr=yahoo&.tsrc=rss,"Sorry, Warren Buffett -- Clovis Oncology, Zoe&apos;s Kitchen, and Laredo Petroleum are great stocks for other investors."
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : June 6, 2017",2017-06-06 15:54:50 +0000,http://finance.yahoo.com/r/43539300-8378-31e1-a3b3-e3fbda57d68c/clovis-oncology-inc-value-analysis-nasdaqclvs-june-6-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Clovis Oncology, Inc. a score of 11. Our analysis is based on comparing Clovis Oncology, Inc. with the following peers – BioMarin Pharmaceutical Inc., Celgene Corporation, TESARO, Inc., AbbVie, Inc., Eli Lilly and Company, Pfizer Inc., Astrazeneca PLC Sponsored ADR, Johnson & Johnson, Cerulean Pharma, Inc. and ... Read more
<b>(Read more...)</b>"
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : June 5, 2017",2017-06-05 12:42:50 +0000,http://finance.yahoo.com/r/57057872-98fb-3407-a783-602e02ee84cf/clovis-oncology-inc-breached-its-50-day-moving-average-in-a-bullish-manner-clvs-us-june-5-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Clovis Oncology, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
<b>(Read more...)</b>"
CLVS,CLVS:UW,BBG001S2DKJ3,Implied Volatility Surging for Clovis (CLVS) Stock Options,2017-06-02 14:34:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7gMUqvpmv0M/implied-volatility-surging-for-clovis-clvs-stock-options-cm797892,Investors in Clovis Oncology Inc CLVS need to pay close attention to the stock based on moves in the options market lately That is because the July 21 st 2017 45 Put had some of the highest implied volatility of all equity options today What is Implied Volatility Implied
CLVS,CLVS:UW,BBG001S2DKJ3,Implied Volatility Surging for Clovis (CLVS) Stock Options,2017-06-02 12:50:12 +0000,https://finance.yahoo.com/news/implied-volatility-surging-clovis-clvs-125012706.html?.tsrc=rss,Clovis (CLVS) needs Investors to pay close attention to the stock based on moves in the options market lately.
CLVS,CLVS:UW,BBG001S2DKJ3,"How Clovis, AstraZeneca Could &apos;Muddy&apos; A Potential Deal For Tesaro",2017-06-01 20:07:28 +0000,http://finance.yahoo.com/r/a4d488f1-0e3c-3844-9c15-5dcdb828294c/how-clovis-astrazeneca-could-muddy-a-potential-deal-for-tesaro?src=A00220&yptr=yahoo&.tsrc=rss,"AstraZeneca, Pfizer and Clovis Oncology could slow bidding on Tesaro, an analyst said Thursday."
CLVS,CLVS:UW,BBG001S2DKJ3,"Commit To Purchase Clovis Oncology At $40, Earn 24.8% Annualized Using Options",2017-05-26 17:33:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z-r6N6myd0s/commit-to-purchase-clovis-oncology-at-40-earn-248-annualized-using-options-cm795415,Investors considering a purchase of Clovis Oncology Inc Symbol CLVS shares but cautious about paying the going market price of 53 32 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Presentations at 2017 ASCO Annual Meeting,2017-05-23 12:00:00 +0000,https://finance.yahoo.com/news/clovis-oncology-announces-presentations-2017-120000700.html?.tsrc=rss,"Clovis Oncology, Inc. today announced that abstracts highlighting progress in the rucaparib clinical development program will be presented at the 2017 American Society of Clinical Oncology Annual Meeting taking place June 2-6 in Chicago."
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain",2017-05-22 15:15:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t5DLe4koMvQ/clovis-clvs-parp-inhibtor-shows-promise-risks-remain-cm792584,On May 19 we issued an updated research report on Boulder CO based Clovis Oncology Inc CLVS Clovis is a biopharmaceutical company focused on the development and commercialization of treatments targeting specific subsets of cancer population So far this year Clovis share price has
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis&apos; (CLVS) PARP Inhibtor Shows Promise, Risks Remain",2017-05-22 12:58:12 +0000,https://finance.yahoo.com/news/clovis-apos-clvs-parp-inhibtor-125812117.html?.tsrc=rss,"On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS)."
CLVS,CLVS:UW,BBG001S2DKJ3,Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug?,2017-05-17 21:05:29 +0000,http://finance.yahoo.com/r/291d105f-b6df-3ba0-ba52-e6922c429a46/did-this-astrazeneca-rival-just-launch-a-potential-blockbuster-drug?src=A00220&yptr=yahoo&.tsrc=rss,"An analyst upgraded Clovis ahead of a key study for its ovarian cancer drug, which he said holds up against another from AstraZeneca."
CLVS,CLVS:UW,BBG001S2DKJ3,Edited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT,2017-05-12 21:21:01 +0000,https://finance.yahoo.com/news/edited-transcript-clvs-earnings-conference-083250473.html?.tsrc=rss,Q1 2017 Clovis Oncology Inc Earnings Call
CLVS,CLVS:UW,BBG001S2DKJ3,Edited Transcript of CLVS earnings conference call or presentation 3-May-17 8:30pm GMT,2017-05-08 00:20:44 +0000,http://finance.yahoo.com/news/edited-transcript-clvs-earnings-conference-083250473.html?.tsrc=rss,Q1 2017 Clovis Oncology Inc Earnings Call
CLVS,CLVS:UW,BBG001S2DKJ3,"How Clovis Might Still Quash AstraZeneca, Tesaro In Cancer",2017-05-04 20:48:27 +0000,http://finance.yahoo.com/r/2942fdee-12e8-3f92-bf97-7a71871c2191/how-clovis-might-still-quash-astrazeneca-tesaro-in-cancer?src=A00220&yptr=yahoo&.tsrc=rss,Clovis stock toppled to a four-month low Thursday on losses but analysts remained bullish on ovarian cancer drug Rubraca which topped views by $2 million.
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech Stock Mailbag: Why Clovis Oncology Is Trading Lower on Rubraca Study Update,2017-05-04 17:29:00 +0000,http://finance.yahoo.com/r/d66c5447-1db8-3629-8b82-2ccb847bd412/biotech-stock-mailbag-why-clovis-oncology-is-trading-lower-on-rubraca-study-update.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start",2017-05-04 16:15:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XGonzqZ11n4/clovis-clvs-q1-loss-narrows-rubraca-off-to-a-good-start-cm784233,Clovis Oncology Inc CLVS reported first quarter 2017 loss of 1 33 per share which was narrower than the Zacks Consensus Estimate of a loss of 1 43 as well as the year ago loss of 2 17 per share In Dec 2016 Clovis received accelerated approval from the FDA for its PARP inhibitor
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis (CLVS) Q1 Loss Narrows, Rubraca Off to a Good Start",2017-05-04 14:27:02 +0000,http://finance.yahoo.com/news/clovis-clvs-q1-loss-narrows-142702011.html?.tsrc=rss,"Clovis Oncology, Inc. (CLVS) reported first-quarter 2017 loss of $1.33 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.43 as well as the year-ago loss of $2.17 per share."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis reports 1Q loss,2017-05-03 21:44:53 +0000,http://finance.yahoo.com/news/clovis-reports-1q-loss-214453436.html?.tsrc=rss,"The Boulder, Colorado-based company said it had a loss of $1.33 per share. Losses, adjusted for stock option expense, were $1.13 per share. The results topped Wall Street expectations. The average estimate ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"Notable Wednesday Option Activity: CLVS, PRU, LITE",2017-05-03 20:50:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LH7vpq3YPLI/notable-wednesday-option-activity-clvs-pru-lite-cm783531,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Clovis Oncology Inc Symbol CLVS where a total volume of 8 047 contracts has been traded thus far today a contract volume which is representative of approximately 804
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces First Quarter 2017 Operating Results,2017-05-03 20:05:00 +0000,http://finance.yahoo.com/news/clovis-oncology-announces-first-quarter-200500481.html?.tsrc=rss,"Clovis Oncology, Inc. reported financial results for the quarter ended March 31, 2017, and provided an update on the Company’s clinical development programs and regulatory outlook for the remainder of 2017."
CLVS,CLVS:UW,BBG001S2DKJ3,Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment,2017-04-27 11:05:00 +0000,http://finance.yahoo.com/news/myriad-genetics-clovis-oncology-sign-110500186.html?.tsrc=rss,"SALT LAKE CITY and BOULDER, Colo., April 27, 2017-- Myriad Genetics, Inc. and Clovis Oncology, Inc. today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Inc Bulls Need a Reality Check,2017-04-25 21:06:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m7JJtnvEgnc/tesaro-inc-bulls-need-a-reality-check-cm779029,Tesaro Inc NASDAQ TSRO enjoyed its best summer ever last year but lately this biotech has had a case of the blues Following a peak in February the stock has lost more than a quarter of its value Despite the recent slide investors should remain braced for further downside
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Inc Bulls Need a Reality Check,2017-04-25 19:43:00 +0000,http://finance.yahoo.com/r/f4370afe-e0df-3f41-b158-c2fb70a538d8/tesaro-inc-bulls-need-a-reality-check.aspx?yptr=yahoo&.tsrc=rss,Has the market overestimated the odds of success for Tesaro&apos;s fancy new cancer drug?
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro's Path to a Billion-Dollar Blockbuster Begins With Pricing,2017-04-21 13:05:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZP6A9S7B3Rs/tesaros-path-to-a-billion-dollar-blockbuster-begins-with-pricing-cm776881,Tesaro NASDAQ TSRO won FDA approval of its new cancer drug Zejula in March and this week management reported that Zejula is now available at a dose of 200 mg per day with a list price of 9 833 per month The price is in the ballpark of existing drugs in Zejula s class and
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro&apos;s Path to a Billion-Dollar Blockbuster Begins With Pricing,2017-04-21 11:21:00 +0000,http://finance.yahoo.com/r/2afc87f8-d8c3-3b80-8022-3fff1121f105/tesaros-path-to-a-billion-dollar-blockbuster-begin.aspx?yptr=yahoo&.tsrc=rss,"Tesaro has set the price of its newly launched PARP inhibitor, Zejula, at nearly $10,000 per month."
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro’s Zejula Flops as H&S Pattern Emerges,2017-04-21 10:52:00 +0000,http://finance.yahoo.com/r/53eed85c-ad7f-3740-8f5d-7f66f04f283a/tesaros-zejula-flops-hs-pattern-emerges-tsro-clvs?partner=YahooSA&yptr=yahoo&.tsrc=rss,A look at Tesaro's recent decline and the bearish head and shoulders pattern emerging in its chart.
CLVS,CLVS:UW,BBG001S2DKJ3,"Tesaro Dives On &apos;Sticker Shock&apos; For $177,000 Drug",2017-04-20 20:22:10 +0000,http://finance.yahoo.com/r/057f0ee2-eef0-346b-81e3-330f397da515/tesaro-dives-on-sticker-shock-boosting-clovis-astrazeneca?src=A00220&yptr=yahoo&.tsrc=rss,"Tesaro stock plunged 10% Thursday on &quot;sticker shock&quot; after announcing its $177,000 annual price tag for ovarian cancer drug Zejula."
CLVS,CLVS:UW,BBG001S2DKJ3,AbbVie's PARP Inhibitor Comes Up Empty,2017-04-20 19:03:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MhiMo2VnZ58/abbvies-parp-inhibitor-comes-up-empty-cm776587,AbbVie s NYSE ABBV attempt to expand the use of a new class of cancer drugs into new indications has failed to pan out according to management The company announced yesterday that two trials evaluating its PARP inhibitor veliparib came up short of their primary endpoints
CLVS,CLVS:UW,BBG001S2DKJ3,AbbVie&apos;s PARP Inhibitor Comes Up Empty,2017-04-20 17:21:00 +0000,http://finance.yahoo.com/r/94a3e85b-772e-3d65-a6ad-d18d1982219f/abbvies-parp-inhibitor-comes-up-empty.aspx?yptr=yahoo&.tsrc=rss,The drugmaker reported that veliparib failed to outperform standard treatment in breast cancer and non-small-cell lung cancer trials.
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Announce First Quarter 2017 Financial Results and Host Webcast Conference Call on May 3,2017-04-20 12:00:00 +0000,http://finance.yahoo.com/news/clovis-oncology-announce-first-quarter-120000316.html?.tsrc=rss,"Clovis Oncology, Inc. will announce its first quarter 2017 financial results on Wednesday, May 3, 2017, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m."
CLVS,CLVS:UW,BBG001S2DKJ3,3 Cancer Drug Stocks That Could Make You Rich,2017-04-17 13:57:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xpDwbhshm1w/3-cancer-drug-stocks-that-could-make-you-rich-cm774471,There are more promising cancer treatments in development now than at any other point in human history That s great news for cancer patients It s also good news for investors looking for stocks with significant potential Three cancer drug stocks in particular could be huge winners
CLVS,CLVS:UW,BBG001S2DKJ3,3 Cancer Drug Stocks That Could Make You Rich,2017-04-17 12:42:00 +0000,http://finance.yahoo.com/r/459e81e5-f459-3d2c-b8af-96a2ec5bb4eb/3-cancer-drug-stocks-that-could-make-you-rich.aspx?yptr=yahoo&.tsrc=rss,"Agios, Celldex, and Clovis stand out as cancer drug stocks that could generate big returns."
CLVS,CLVS:UW,BBG001S2DKJ3,Today's Research Reports on Biotech Stocks to Watch: Nektar Therapeutics and Clovis Oncology,2017-04-10 13:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-biotech-stocks-133000525.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 10, 2017 / The iShares NASDAQ Biotechnology Index ETF gained 0.80 percent to close at 290.52, up 9.47 percent year-to-date. Nektar Therapeutics and Clovis Oncology have ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology's Stock Edged Higher in March,2017-04-07 22:54:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kk-9Zq02SHA/why-clovis-oncologys-stock-edged-higher-in-march-cm771643,What happened According to data from S amp P Global Market Intelligence shares of Clovis Oncology NASDAQ CLVS gained 7 42 in March The drugmaker s shares are now up almost 28 so far this year due to the Food and Drug Administration s FDA approval of its 160
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology&apos;s Stock Edged Higher in March,2017-04-07 20:53:00 +0000,http://finance.yahoo.com/r/5dd541b9-3fc4-3c45-bee3-8cf226cc2d65/why-clovis-oncologys-stock-edged-higher-in-march.aspx?yptr=yahoo&.tsrc=rss,"Investors are clearly excited about Clovis&apos; new ovarian cancer drug, but this enthusiasm may be overdone at this point."
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31, 2017",2017-03-31 12:33:20 +0000,http://www.capitalcube.com/blog/index.php/clovis-oncology-inc-breached-its-50-day-moving-average-in-a-bearish-manner-clvs-us-march-31-2017/,"Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31, 2017"
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : March 31, 2017",2017-03-31 12:33:20 +0000,http://finance.yahoo.com/r/fe017124-4630-3541-b74c-aa5ab8e5e4af/clovis-oncology-inc-breached-its-50-day-moving-average-in-a-bearish-manner-clvs-us-march-31-2017?yptr=yahoo&.tsrc=rss,"Categories:   ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Clovis Oncology, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more    
<b>(Read more...)</b>"
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA,2017-03-29 17:59:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9LJOp-SNS1k/astrazenecas-azn-lynparza-nda-accepted-for-review-by-fda-cm767346,AstraZeneca plc AZN announced that the FDA has accepted the new drug application NDA for Lynparza 300mg twice daily for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation The drug has also been granted a
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA,2017-03-29 15:41:03 +0000,http://finance.yahoo.com/news/astrazenecas-azn-lynparza-nda-accepted-154103204.html?.tsrc=rss,AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA,2017-03-29 15:41:03 +0000,http://finance.yahoo.com/news/astrazenecas-azn-lynparza-nda-accepted-154103204.html,AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Nets Surprise Early Approval,2017-03-29 15:00:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JEwZs1TckUo/tesaro-nets-surprise-early-approval-cm767147,Tesaro s NASDAQ TSRO 160 ovarian cancer drug niraparib will begin competing for prescriptions earlier than expected Niraparib which will be sold under the brand name Zejula notched FDA approval on Monday more than three months ahead of its June 30 decision date The
CLVS,CLVS:UW,BBG001S2DKJ3,[$$] Overheard,2017-03-29 04:10:22 +0000,http://finance.yahoo.com/r/c19d7ce8-6b77-3ed9-b845-1ad11d9863a3/SB22711645461998504051204583050881584167100.html?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Who said day trading was easy money?
CLVS,CLVS:UW,BBG001S2DKJ3,[$$] Overheard,2017-03-29 04:10:22 +0000,http://online.wsj.com/article/SB22711645461998504051204583050881584167100.html?ru=yahoo?mod=yahoo_itp,[$$] Overheard
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula,2017-03-28 23:58:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/foeZBBVDAM0/tesaro-wins-fda-approval-for-ovarian-cancer-drug-zejula-cm766956,Tesaro Inc TSRO recently announced that the FDA has approved its oral once daily poly ADP ribose polymerase PARP inhibitor Zejula niraparib for the maintenance treatment of women suffering from recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula,2017-03-28 22:03:00 +0000,http://www.investopedia.com/partner/zacks/tesaro-wins-fda-approval-ovarian-cancer-drug-zejula/?partner=YahooSA,Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula,2017-03-28 22:03:00 +0000,http://finance.yahoo.com/r/10dda2d0-88f3-3efe-834e-b0cda96fb6b9/tesaro-wins-fda-approval-ovarian-cancer-drug-zejula?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Tesaro, Inc. TSRO recently announced that the FDA has approved its oral, once-daily poly(ADP-ribose) polymerase (PARP) inhibitor Zejula (niraparib)for the maintenance treatment of women suffering from ..."
CLVS,CLVS:UW,BBG001S2DKJ3,5:28 pm Clovis Oncology announces four data presentations for AACR April 1-5 Meeting that will provide new insights into rucaparib's mechanism of action and function in multiple disease and therapy settings,2017-03-28 21:28:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#clvs,5:28 pm Clovis Oncology announces four data presentations for AACR April 1-5 Meeting that will provide new insights into rucaparib's mechanism of action and function in multiple disease and therapy settings
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017,2017-03-28 20:30:00 +0000,http://finance.yahoo.com/news/clovis-oncology-announces-data-presentations-203000786.html,"[Business Wire] - Clovis Oncology, Inc. today announced that rucaparib preclinical data will be presented at the American Association for Cancer Research Annual Meeting 2017. AACR will take place April 1-5, 2017 in Washington, DC."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017,2017-03-28 20:30:00 +0000,http://finance.yahoo.com/news/clovis-oncology-announces-data-presentations-203000786.html?.tsrc=rss,"Clovis Oncology, Inc. today announced that rucaparib preclinical data will be presented at the American Association for Cancer Research Annual Meeting 2017. AACR will take place April 1-5, 2017 in Washington, DC."
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer,2017-03-28 20:19:53 +0000,http://finance.yahoo.com/r/2aeb7684-98dd-3bdc-b486-5f26a77edeca/why-clovis-advantage-might-squash-tesaro-in-ovarian-cancer?src=A00220A&yptr=yahoo&.tsrc=rss,"Clovis' Rubraca label is &quot;cleanest,&quot; an analyst said Tuesday, a day after the FDA approved Tesaro's Zejula in ovarian cancer."
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer,2017-03-28 20:19:53 +0000,http://www.investors.com/news/technology/why-clovis-advantage-might-squash-tesaro-in-ovarian-cancer/?src=A00220A,Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech M&A Trade Hits a Snag,2017-03-28 13:23:06 +0000,http://blogs.wsj.com/moneybeat/2017/03/28/biotech-ma-trade-hits-a-snag/?mod=yahoo_hs,Biotech M&A Trade Hits a Snag
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech M&A Trade Hits a Snag,2017-03-28 13:23:06 +0000,http://finance.yahoo.com/r/a3a71f31-28c7-3a96-8cc3-49af72f5aa93/biotech-ma-trade-hits-a-snag?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Who said day trading was easy money?
CLVS,CLVS:UW,BBG001S2DKJ3,BUZZ-AstraZeneca cancer drug faces new competition from Tesaro,2017-03-28 10:42:58 +0000,http://uk.finance.yahoo.com/news/buzz-astrazeneca-cancer-drug-faces-104258481.html,BUZZ-AstraZeneca cancer drug faces new competition from Tesaro
CLVS,CLVS:UW,BBG001S2DKJ3,Why Is Clovis  (CLVS) Up 18.8% Since the Last Earnings Report?,2017-03-28 09:58:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/78E9QUeUbWc/why-is-clovis-clvs-up-188-since-the-last-earnings-report-cm766301,It has been about a month since the last earnings report for Clovis Oncology Inc CLVS Shares have added about 18 8 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before
CLVS,CLVS:UW,BBG001S2DKJ3,Why Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report?,2017-03-28 07:30:07 +0000,http://finance.yahoo.com/news/why-clovis-clvs-18-8-073007111.html,Why Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report?
CLVS,CLVS:UW,BBG001S2DKJ3,Why Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report?,2017-03-28 07:30:07 +0000,http://finance.yahoo.com/news/why-clovis-clvs-18-8-073007111.html?.tsrc=rss,Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CLVS,CLVS:UW,BBG001S2DKJ3,"FDA Nod For TSRO, DÃ©jÃ  Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz",2017-03-28 04:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pzEgcbmaO5Y/fda-nod-for-tsro-d%C3%A3j%C3%A3%C2%A0-vu-for-arql-fomx-plunges-on-trial-data-selb-abuzz-20170328-00134,"FDA Nod For TSRO, DÃ©jÃ  Vu For ARQL, FOMX Plunges On Trial Data, SELB Abuzz"
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro wins FDA approval for potential blockbuster cancer drug,2017-03-28 00:42:15 +0000,http://www.bizjournals.com/boston/news/2017/03/27/tesaro-wins-approval-for-potential-blockbuster.html?ana=yahoo,Tesaro wins FDA approval for potential blockbuster cancer drug
CLVS,CLVS:UW,BBG001S2DKJ3,"Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely",2017-03-27 20:33:30 +0000,http://www.investors.com/news/technology/why-tesaros-odds-of-being-acquired-have-tanked-as-astrazeneca-looms/?src=A00220A,"Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely"
CLVS,CLVS:UW,BBG001S2DKJ3,"Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely",2017-03-27 20:33:30 +0000,http://finance.yahoo.com/r/555a1f94-bd67-3880-b282-e59d7365947d/why-tesaros-odds-of-being-acquired-have-tanked-as-astrazeneca-looms?src=A00220A&yptr=yahoo&.tsrc=rss,"Tesaro stock fell as oncologists concluded rival drugs are just as effective as its ovarian cancer drug, hurting Tesaro's merger prospects."
CLVS,CLVS:UW,BBG001S2DKJ3,Cancer Drug's Shortcomings Hurt Company's Merger Prospects,2017-03-27 20:05:30 +0000,http://finance.yahoo.com/r/b70be729-5380-3837-bfaf-6ca135c988c1/why-tesaros-odds-of-being-acquired-have-tanked-as-astrazeneca-looms-branch?src=A00220A&yptr=yahoo&.tsrc=rss,"Tesaro stock fell as oncologists concluded rival drugs are just as effective as its ovarian cancer drug, hurting Tesaro's merger prospects."
CLVS,CLVS:UW,BBG001S2DKJ3,"SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of the Board of Directors of Clovis Oncology, Inc. - CLVS",2017-03-24 22:35:00 +0000,http://finance.yahoo.com/news/shareholder-alert-law-office-brodsky-223500159.html,"[Accesswire] - BALA CYNWYD, PA / ACCESSWIRE / March 24, 2017 / The law Office of Brodsky & Smith, LLC announces an investigation of the Board of Directors of Clovis Oncology, Inc. (""Clovis"" or the ""Company"") ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of the Board of Directors of Clovis Oncology, Inc. - CLVS",2017-03-24 22:35:00 +0000,http://finance.yahoo.com/news/shareholder-alert-law-office-brodsky-223500159.html?.tsrc=rss,"BALA CYNWYD, PA / ACCESSWIRE / March 24, 2017 / The law Office of Brodsky & Smith, LLC announces an investigation of the Board of Directors of Clovis Oncology, Inc. (""Clovis"" or the ""Company"") ..."
CLVS,CLVS:UW,BBG001S2DKJ3,3 Stocks at 52-Week Highs Still Worth Buying,2017-03-22 14:09:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4mmn8yCvquI/3-stocks-at-52-week-highs-still-worth-buying-cm763990,With the broader markets hovering around their all time highs at the moment 160 the idea of buying individual stocks that are at or close to their 52 week highs may not sound all that appealing Stocks with the richest valuations after all are likely to be the hardest hit in the
CLVS,CLVS:UW,BBG001S2DKJ3,3 Stocks at 52-Week Highs Still Worth Buying,2017-03-22 12:02:00 +0000,https://www.fool.com/investing/2017/03/22/3-stocks-at-52-week-highs-still-worth-buying.aspx,3 Stocks at 52-Week Highs Still Worth Buying
CLVS,CLVS:UW,BBG001S2DKJ3,3 Stocks at 52-Week Highs Still Worth Buying,2017-03-22 12:02:00 +0000,http://finance.yahoo.com/r/c23374d7-1fb2-3a93-8d13-3cef468e6229/3-stocks-at-52-week-highs-still-worth-buying.aspx?yptr=yahoo&.tsrc=rss,These three high-flying stocks still have room to run.
CLVS,CLVS:UW,BBG001S2DKJ3,Billionaires' Best Healthcare Stock Picks of 2017 (So Far),2017-03-21 21:09:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZGJWbPLlDBU/billionaires-best-healthcare-stock-picks-of-2017-so-far-cm763781,Billionaire investors didn t amass their fortunes by picking horrible stocks While you wouldn t want to blindly copy these successful investors it certainly doesn t hurt to watch which stocks they choose and how those stocks perform I looked at the portfolios of several of
CLVS,CLVS:UW,BBG001S2DKJ3,Billionaires' Best Healthcare Stock Picks of 2017 (So Far),2017-03-21 19:02:00 +0000,https://www.fool.com/investing/2017/03/21/billionaires-best-healthcare-stock-picks-of-2017-s.aspx,Billionaires' Best Healthcare Stock Picks of 2017 (So Far)
CLVS,CLVS:UW,BBG001S2DKJ3,Billionaires' Best Healthcare Stock Picks of 2017 (So Far),2017-03-21 19:02:00 +0000,http://finance.yahoo.com/r/9f08b028-c429-393a-9ff5-1ffec2af0934/billionaires-best-healthcare-stock-picks-of-2017-s.aspx?yptr=yahoo&.tsrc=rss,"Why billionaire investors are loving Immunomedics, Achaogen, AveXis, Exact Sciences, and Clovis Oncology this year."
CLVS,CLVS:UW,BBG001S2DKJ3,Look for Clovis Oncology to Resume Its Advance,2017-03-20 19:37:00 +0000,http://realmoney.thestreet.com/articles/03/20/2017/look-clovis-oncology-resume-its-advance?puc=yahoo&cm_ven=YAHOO,Look for Clovis Oncology to Resume Its Advance
CLVS,CLVS:UW,BBG001S2DKJ3,Look for Clovis Oncology to Resume Its Advance,2017-03-20 19:37:00 +0000,http://finance.yahoo.com/r/3bd694d3-4c7b-327c-851f-100a00fd76bc/look-clovis-oncology-resume-its-advance?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,More gains await patient CLVS holders.
CLVS,CLVS:UW,BBG001S2DKJ3,5 Biotech Companies To Watch In 2017,2017-03-17 13:33:35 +0000,http://ir.baystreet.ca/article.aspx?id=527&1489757615,5 Biotech Companies To Watch In 2017
CLVS,CLVS:UW,BBG001S2DKJ3,5 Biotech Companies Set for Major Breakouts In 2017,2017-03-17 11:30:00 +0000,http://finance.yahoo.com/news/5-biotech-companies-set-major-003000416.html?.tsrc=rss,5 Biotech Companies Set for Major Breakouts In 2017
CLVS,CLVS:UW,BBG001S2DKJ3,5 Biotech Companies Set for Major Breakouts In 2017,2017-03-17 11:30:00 +0000,http://finance.yahoo.com/news/5-biotech-companies-set-major-003000416.html,5 Biotech Companies Set for Major Breakouts In 2017
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca PLC (ADR) (AZN)’s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO),2017-03-16 18:49:51 +0000,http://www.insidermonkey.com/blog/astrazeneca-plc-adr-azns-lynparza-trial-results-positive-in-competitive-threat-to-clovis-oncology-inc-clvs-and-tesaro-inc-tsro-566916/,AstraZeneca PLC (ADR) (AZN)’s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO)
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca PLC (ADR) (AZN)’s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO),2017-03-16 18:49:51 +0000,http://finance.yahoo.com/r/87f15a76-a765-3273-8377-03277b203a20/astrazeneca-plc-adr-azns-lynparza-trial-results-positive-in-competitive-threat-to-clovis-oncology-inc-clvs-and-tesaro-inc-tsro-566916?yptr=yahoo&.tsrc=rss,"Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression. AstraZeneca PLC (ADR) (NYSE:AZN) now hopes that the use of the PARP inhibitor will be widened. The trial revealed that women who are suffering from ovarian cancer and who have a BRCA gene that is […]"
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca Fires Back at Tesaro in Ovarian Cancer,2017-03-16 14:08:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HIpBAkuRGLk/astrazeneca-fires-back-at-tesaro-in-ovarian-cancer-cm761554,The PARP battle is on Following news that AstraZeneca s NYSE AZN PARP inhibiting cancer drug Lynparza delivered a big win in phase 3 studies all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity
CLVS,CLVS:UW,BBG001S2DKJ3,3 tech and biotech stocks with momentum,2017-03-16 12:52:11 +0000,http://finance.yahoo.com/r/3457ed09-6352-3ce1-8f39-eab65458c116/Story.aspx?guid=DBCDD42A-09BF-11E7-9108-9B9BDCA7849D&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Harry Boxer is tracking bluebird bio, Clovis Oncology and Boingo Wireless."
CLVS,CLVS:UW,BBG001S2DKJ3,3 tech and biotech stocks with momentum,2017-03-16 12:52:11 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=DBCDD42A-09BF-11E7-9108-9B9BDCA7849D&siteid=yhoof2,3 tech and biotech stocks with momentum
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Sell-Off On AstraZeneca Ovarian Cancer Trial Overdone: Analyst,2017-03-15 20:15:32 +0000,http://www.investors.com/news/technology/tesaro-selloff-on-astrazeneca-ovarian-cancer-trial-overdone-analyst/?src=A00220A,Tesaro Sell-Off On AstraZeneca Ovarian Cancer Trial Overdone: Analyst
CLVS,CLVS:UW,BBG001S2DKJ3,"Here’s What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS)",2017-03-15 17:54:18 +0000,http://www.insidermonkey.com/blog/heres-what-just-happened-with-astrazeneca-plc-adr-azn-tesaro-inc-tsro-and-clovis-oncology-inc-clvs-566628/,"Here’s What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS)"
CLVS,CLVS:UW,BBG001S2DKJ3,Lynparza Vs. Niraparib,2017-03-15 12:32:58 +0000,http://finance.yahoo.com/news/lynparza-vs-niraparib-123258941.html,Lynparza Vs. Niraparib
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Shares Reiterated As A Sell Following 10% Rally,2017-03-15 12:08:13 +0000,http://finance.yahoo.com/news/clovis-shares-reiterated-sell-following-120813609.html,Clovis Shares Reiterated As A Sell Following 10% Rally
CLVS,CLVS:UW,BBG001S2DKJ3,Goldman Sachs Raises Clovis Oncology Price Target to $75,2017-03-15 11:46:00 +0000,https://www.thestreet.com/story/14043896/1/goldman-sachs-raises-clovis-oncology-price-target-to-75.html?puc=yahoo&cm_ven=YAHOO,Goldman Sachs Raises Clovis Oncology Price Target to $75
CLVS,CLVS:UW,BBG001S2DKJ3,6 Stocks Trending Up With Major Volume,2017-03-15 11:30:00 +0000,https://www.thestreet.com/story/14043606/1/6-stocks-trending-up-with-major-volume.html?puc=yahoo&cm_ven=YAHOO,6 Stocks Trending Up With Major Volume
CLVS,CLVS:UW,BBG001S2DKJ3,"Gainers & Losers Of Mar.14: CVRS, OCX, OFIX, PETX, AMPH...",2017-03-14 23:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e_aDcecsHjA/gainers--losers-of-mar14-cvrs-ocx-ofix-petx-amph-20170314-01326,"Gainers & Losers Of Mar.14: CVRS, OCX, OFIX, PETX, AMPH..."
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Trips On AstraZeneca's Ovarian Cancer Trial While Clovis Climbs,2017-03-14 20:17:13 +0000,http://www.investors.com/news/technology/tesaro-trips-on-astrazenecas-ovarian-cancer-trial-while-clovis-climbs/?src=A00220A,Tesaro Trips On AstraZeneca's Ovarian Cancer Trial While Clovis Climbs
CLVS,CLVS:UW,BBG001S2DKJ3,Why Tesaro is Tanking,2017-03-14 20:09:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/14/why-tesaro-is-tanking/?mod=yahoobarrons&ru=yahoo,Why Tesaro is Tanking
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results,2017-03-14 19:43:00 +0000,https://www.thestreet.com/story/14043007/1/astrazeneca-takes-parp-inhibitor-fight-to-rival-tesaro-with-strong-ovarian-cancer-study-results.html?puc=yahoo&cm_ven=YAHOO,AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca ovarian cancer drug slows disease markedly in study,2017-03-14 19:38:57 +0000,http://uk.finance.yahoo.com/news/astrazeneca-ovarian-cancer-drug-slows-193857570.html,AstraZeneca ovarian cancer drug slows disease markedly in study
CLVS,CLVS:UW,BBG001S2DKJ3,AstraZeneca ovarian cancer drug slows disease markedly in study,2017-03-14 18:30:01 +0000,http://uk.finance.yahoo.com/news/astrazeneca-ovarian-cancer-drug-slows-183001992.html,AstraZeneca ovarian cancer drug slows disease markedly in study
CLVS,CLVS:UW,BBG001S2DKJ3,SPDR S&P Biotech ETF Experiences Big Inflow,2017-03-14 16:08:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xl2X0nxLMSY/spdr-sp-biotech-etf-experiences-big-inflow-cm760568,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 110 8 million dollar inflow that s a 3 6 increase week over week in outstanding
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women’s Cancer,2017-03-12 14:30:00 +0000,http://finance.yahoo.com/news/clovis-oncology-presents-data-phase-143000211.html,"[Business Wire] - Clovis Oncology, Inc. announced new data from parts 1 and 2 of the ongoing ARIEL2 Phase 2 study being presented today at the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in National Harbor, MD."
CLVS,CLVS:UW,BBG001S2DKJ3,"XBI, CLVS, KITE, TSRO: Large Inflows Detected at ETF",2017-03-02 17:12:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jmMZ2Tyw1_U/xbi-clvs-kite-tsro-large-inflows-detected-at-etf-cm755447,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the SPDR S amp P Biotech ETF Symbol XBI where we have detected an approximate 232 5 million dollar inflow that s a 8 2 increase week over week in outstanding
CLVS,CLVS:UW,BBG001S2DKJ3,"Tesaro Eyes Immuno-Oncology As AstraZeneca, Clovis Loom: Analyst",2017-03-01 21:22:09 +0000,http://www.investors.com/news/technology/tesaro-eyes-i-o-market-as-astrazeneca-clovis-rivalries-mount-leerink/,"Tesaro Eyes Immuno-Oncology As AstraZeneca, Clovis Loom: Analyst"
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Financials",2017-03-01 18:04:09 +0000,http://finance.yahoo.com/q/is?s=clvs,"CLOVIS ONCOLOGY, INC. Financials"
CLVS,CLVS:UW,BBG001S2DKJ3,Merrill Lynch Raises Price Targets on 3 Red-Hot Tech and Biotech Stocks,2017-02-24 15:20:19 +0000,http://finance.yahoo.com/news/merrill-lynch-raises-price-targets-152019904.html,Merrill Lynch Raises Price Targets on 3 Red-Hot Tech and Biotech Stocks
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 10-K, Annual Report",2017-02-23 22:19:31 +0000,http://biz.yahoo.com/e/170223/clvs10-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 10-K, Annual Report"
CLVS,CLVS:UW,BBG001S2DKJ3,"Commit To Purchase Clovis Oncology At $35, Earn 12.3% Using Options",2017-02-23 18:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8C5uPeZ5tGQ/commit-to-purchase-clovis-oncology-at-35-earn-123-using-options-cm752214,Investors considering a purchase of Clovis Oncology Inc Symbol CLVS shares but tentative about paying the going market price of 58 51 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology 4Q Loss Below Street Estimates,2017-02-23 15:48:00 +0000,http://www.investopedia.com/news/clovis-oncology-4q-loss-misses-street-clvs/?partner=YahooSA,Clovis Oncology 4Q Loss Below Street Estimates
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca,2017-02-23 14:50:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bfUJNCm_uis/clovis-clvs-q4-loss-wider-than-expected-focus-on-rubraca-cm751913,Clovis Oncology Inc CLVS reported fourth quarter 2016 loss of 1 83 per share wider than the Zacks Consensus Estimate of a loss of 1 65 However the loss was much narrower than the year ago loss of 2 23 per share Clovis did not generate significant revenues in the reported quarter as
CLVS,CLVS:UW,BBG001S2DKJ3,[2/23] This Week’s Earnings Revisions Movers,2017-02-23 14:39:09 +0000,http://finance.yahoo.com/tumblr/blog-223-this-weeks-earnings-revisions-movers-143916542.html,[2/23] This Week’s Earnings Revisions Movers
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca,2017-02-23 13:59:01 +0000,http://finance.yahoo.com/news/clovis-clvs-q4-loss-wider-135901758.html,Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
CLVS,CLVS:UW,BBG001S2DKJ3,Edited Transcript of CLVS earnings conference call or presentation 22-Feb-17 9:30pm GMT,2017-02-23 04:58:38 +0000,http://finance.yahoo.com/news/edited-transcript-clvs-earnings-conference-045838608.html,Edited Transcript of CLVS earnings conference call or presentation 22-Feb-17 9:30pm GMT
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis reports 4Q loss,2017-02-22 22:06:26 +0000,http://sg.finance.yahoo.com/news/clovis-reports-4q-loss-220626898.html,Clovis reports 4Q loss
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today,2017-02-22 21:30:00 +0000,http://biz.yahoo.com/cc/8/155638.html,Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh",2017-02-22 21:14:31 +0000,http://biz.yahoo.com/e/170222/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces 2016 Operating Results,2017-02-22 21:05:00 +0000,http://finance.yahoo.com/news/clovis-oncology-announces-2016-operating-210500952.html,"[Business Wire] - Clovis Oncology, Inc. reported financial results for the quarter and year ended December 31, 2016, and provided an update on the Company’s clinical development programs and regulatory outlook for 2017."
CLVS,CLVS:UW,BBG001S2DKJ3,"XBI, JPNL: Big ETF Outflows",2017-02-22 17:51:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pDevT0R2nTA/xbi-jpnl-big-etf-outflows-cm751393,Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel the biggest outflow was seen in the SPDR S amp P Biotech ETF XBI where 1 800 000 units were destroyed or a 4 3 decrease week over week Among the largest underlying components of XBI
CLVS,CLVS:UW,BBG001S2DKJ3,"Johnson & Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation",2017-02-19 01:41:00 +0000,http://finance.yahoo.com/news/johnson-weaver-llp-announces-investigations-014100177.html,"[PR Newswire] - Johnson & Weaver, LLP is investigating potential violations of federal and state securities laws by Clovis Oncology, Inc. (CLVS) and certain of its officers. On November 19, 2015, a class action lawsuit was filed against Clovis over alleged securities laws violations."
CLVS,CLVS:UW,BBG001S2DKJ3,"Noteworthy Friday Option Activity: SAGE, BAX, CLVS",2017-02-17 21:51:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i4C2RjUcrKo/noteworthy-friday-option-activity-sage-bax-clvs-cm749833,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Sage Therapeutics Inc Symbol SAGE where a total volume of 2 971 contracts has been traded thus far today a contract volume which is representative of approximately 297
CLVS,CLVS:UW,BBG001S2DKJ3,"AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink",2017-02-17 21:31:05 +0000,http://www.investors.com/news/technology/astrazeneca-could-give-pfizer-tesaro-leg-up-in-breast-cancer-leerink/,"AstraZeneca Could Give Pfizer, Tesaro Leg Up In Breast Cancer: Leerink"
CLVS,CLVS:UW,BBG001S2DKJ3,"Boxer Capital, LLC Buys AveXis, BeiGene, Alnylam Pharmaceuticals, Sells Biomarin ...",2017-02-17 20:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XwYgiiI0jBI/boxer-capital-llc-buys-avexis-beigene-alnylam-pharmaceuticals-sells-biomarin-cm749825,Boxer Capital LLC New Purchases ALNY ALXN SBBP SNSS BLPH RXDX Added Positions AVXS BGNE MDCO Reduced Positions SGEN CLVS ARDM Sold Out BMRN RIGL HRTX EBIO EPIX New Purchases ALNY ALXN SBBP SNSS BLPH RXDX
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis, Tesaro Soar on Astrazeneca Phase Three News",2017-02-17 18:38:00 +0000,https://www.thestreet.com/story/14007046/1/clovis-tesaro-soar-on-astrazeneca-phase-three-news.html?puc=yahoo&cm_ven=YAHOO,"Clovis, Tesaro Soar on Astrazeneca Phase Three News"
CLVS,CLVS:UW,BBG001S2DKJ3,Update in Lawsuit for Investors in shares of Clovis Oncology Inc (NASDAQ:CLVS) announced by Shareholders Foundation,2017-02-14 17:40:00 +0000,http://finance.yahoo.com/news/lawsuit-investors-shares-clovis-oncology-174000132.html,"[GlobeNewswire] - SAN DIEGO, Feb. 14, 2017-- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Colorado on behalf of certain purchasers of shares of Clovis Oncology Inc over alleged Securities Laws ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"XBI, UGE: Big ETF Outflows",2017-02-14 17:18:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nxe_oV5ft0Y/xbi-uge-big-etf-outflows-cm747682,Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel the biggest outflow was seen in the XBI SPDR S amp P Biotech ETF US Equities XBI where 1 800 000 units were destroyed or a 4 2 decrease week over week Among the largest
CLVS,CLVS:UW,BBG001S2DKJ3,"Morgan Stanley, Twitter, Tesaro: Doug Kass' Views",2017-02-13 06:00:00 +0000,https://www.thestreet.com/story/13998995/1/morgan-stanley-twitter-tesaro-doug-kass-views.html?puc=yahoo&cm_ven=YAHOO,"Morgan Stanley, Twitter, Tesaro: Doug Kass' Views"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Announce Fourth Quarter/Year-End 2016 Financial Results and Host Webcast Conference Call on February 22,2017-02-09 23:05:00 +0000,http://finance.yahoo.com/news/clovis-oncology-announce-fourth-quarter-230500933.html,"[Business Wire] - Clovis Oncology, Inc. will announce its fourth quarter/year-end 2016 financial results on Wednesday, February 22, 2017, after the close of the U.S. financial markets."
CLVS,CLVS:UW,BBG001S2DKJ3,3 Scorching Hot Biotech Stocks -- Are They Buys?,2017-02-08 23:18:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lpKiuq-DIDA/3-scorching-hot-biotech-stocks-are-they-buys-cm745212,Making a 70 return in only three months sounds pretty good Three biotech stocks have done just that and more Shares of Clovis Oncology NASDAQ CLVS soared over 120 during the last three months Bluebird bio s NASDAQ BLUE stock jumped more than 80 during the period
CLVS,CLVS:UW,BBG001S2DKJ3,3 Scorching Hot Biotech Stocks -- Are They Buys?,2017-02-08 21:53:03 +0000,http://www.fool.com/investing/2017/02/08/3-scorching-hot-biotech-stocks-are-they-buys.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Scorching Hot Biotech Stocks -- Are They Buys?
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech Tesaro Climbs on Takeout Reports,2017-02-08 17:49:00 +0000,https://www.thestreet.com/story/13994924/1/biotech-tesaro-climbs-on-takeout-reports.html?puc=yahoo&cm_ven=YAHOO,Biotech Tesaro Climbs on Takeout Reports
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology downgraded by Chardan Capital Markets,2017-02-03 11:52:40 +0000,http://finance.yahoo.com/q/ud?s=CLVS,Clovis Oncology downgraded by Chardan Capital Markets
CLVS,CLVS:UW,BBG001S2DKJ3,"Notable ETF Inflow Detected - XBI, CLVS, ACAD, UTHR",2017-02-02 17:32:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pakwiJavqtM/notable-etf-inflow-detected-xbi-clvs-acad-uthr-cm742278,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the XBI SPDR S amp P Biotech ETF US Equities Symbol XBI where we have detected an approximate 136 6 million dollar inflow that s a 5 3 increase week over week
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement",2017-02-01 13:31:10 +0000,http://biz.yahoo.com/e/170201/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program,2017-02-01 13:30:00 +0000,http://finance.yahoo.com/news/clovis-oncology-strata-oncology-announce-133000381.html,"[Business Wire] - Clovis Oncology, Inc. and Strata Oncology, Inc. today announced an agreement to accelerate patient identification and enrollment for Clovis’ ongoing TRITON clinical trial program, which includes Phase 2 and Phase 3 clinical trials of rucaparib in metastatic castration-resistant prostate cancer, both of which are open for enrollment."
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO)",2017-01-31 17:59:43 +0000,http://www.insidermonkey.com/blog/clovis-oncology-inc-clvss-ovarian-cancer-drug-faces-stiff-competition-from-astrazeneca-plc-adr-azn-tesaro-inc-tsro-529367/,"Clovis Oncology Inc (CLVS)’s Ovarian Cancer Drug Faces Stiff Competition From AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO)"
CLVS,CLVS:UW,BBG001S2DKJ3,"Tesaro, AstraZeneca Could Shrink Clovis' Ovarian Cancer Drug Pool",2017-01-30 21:12:10 +0000,http://www.investors.com/news/technology/tesaro-astrazeneca-could-shrink-clovis-ovarian-cancer-drug-pool/,"Tesaro, AstraZeneca Could Shrink Clovis' Ovarian Cancer Drug Pool"
CLVS,CLVS:UW,BBG001S2DKJ3,3 Mid-Cap Biotech Stocks to Buy in February,2017-01-30 12:27:46 +0000,http://www.fool.com/investing/2017/01/29/3-mid-cap-biotech-stocks-to-buy-in-february.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Mid-Cap Biotech Stocks to Buy in February
CLVS,CLVS:UW,BBG001S2DKJ3,3 Mid-Cap Biotech Stocks to Buy in February,2017-01-29 13:31:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yKUzag6Rxiw/3-mid-cap-biotech-stocks-to-buy-in-february-cm739849,Many small cap biotech stocks are super risky with no products on the market yet Some big cap biotech stocks on the other hand aren t growing like they used to Mid cap biotech stocks could meet Goldilocks criteria of finding what is just right Three mid cap biotechs in
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher,2017-01-27 14:33:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FoGH3l953S8/clovis-oncology-clvs-in-focus-stock-moves-56-higher-cm739275,Clovis Oncology Inc CLVS was a big mover last session as the company saw its shares rise above 5 on the day The move came on solid volume with far more shares changing hands than in a normal session This continues the recent uptrend for the company as the stock is now up almost 37 in
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher,2017-01-27 13:40:01 +0000,http://finance.yahoo.com/news/clovis-oncology-clvs-focus-stock-134001860.html,Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher
CLVS,CLVS:UW,BBG001S2DKJ3,Thursday's ETF with Unusual Volume: DWAS,2017-01-26 19:31:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TchaCzJ83XI/thursdays-etf-with-unusual-volume-dwas-cm738865,The PowerShares DWA SmallCap Momentum Portfolio ETF DWAS is seeing unusually high volume in afternoon trading Thursday with over 265 000 shares traded versus three month average volume of about 29 000 Shares of DWAS were down about 0 6 on the day Components of that ETF with
CLVS,CLVS:UW,BBG001S2DKJ3,3 Biotechs Likely to Be Acquired in 2017,2017-01-22 19:37:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q2FHkzXsXlc/3-biotechs-likely-to-be-acquired-in-2017-cm736459,The year is still young but we ve already seen acquisitions of Ariad and CoLucid Which biotechs could be scooped up next in 2017 Here s why Clovis Oncology NASDAQ CLVS Intercept Pharmaceuticals NASDAQ ICPT and Jazz Pharmaceuticals NASDAQ JAZZ could be
CLVS,CLVS:UW,BBG001S2DKJ3,3 Biotechs Likely to Be Acquired in 2017,2017-01-22 18:27:36 +0000,http://www.fool.com/investing/2017/01/22/3-biotechs-likely-to-be-acquired-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs Likely to Be Acquired in 2017
CLVS,CLVS:UW,BBG001S2DKJ3,What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?,2017-01-17 14:40:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ea00drHVAzg/whats-behind-clovis-clvs-one-year-rally-of-1463-cm734183,Shares of Clovis Oncology Inc CLVS got a huge boost in Dec 2016 when the company received accelerated FDA approval for its lead drug Rubraca rucaparib In fact Clovis shares have surged 37 1 in the past one month outperforming the Zacks classified Medical Biomedical and
CLVS,CLVS:UW,BBG001S2DKJ3,What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?,2017-01-17 13:05:01 +0000,http://finance.yahoo.com/news/whats-behind-clovis-clvs-one-130501710.html,What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?
CLVS,CLVS:UW,BBG001S2DKJ3,"Gainers & Losers Of The Day: TBIO, IMMU, SGMO, BIOC, APRI",2017-01-12 23:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tl8bE_NS0ZE/gainers--losers-of-the-day-tbio-immu-sgmo-bioc-apri-20170112-01005,"Gainers & Losers Of The Day: TBIO, IMMU, SGMO, BIOC, APRI"
CLVS,CLVS:UW,BBG001S2DKJ3,"Thursday's ETF Movers: XBI, KRE",2017-01-12 19:57:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AcKZHZf9_L4/thursdays-etf-movers-xbi-kre-cm732937,In trading on Thursday the SPDR S amp P Biotech ETF XBI is outperforming other ETFs up about 1 9 on the day Components of that ETF showing particular strength include shares of Novavax NVAX up about 7 4 and shares of Clovis Oncology CLVS up about 7 2 on the day
CLVS,CLVS:UW,BBG001S2DKJ3,"The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals",2017-01-10 16:55:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nl9UeYCPzZI/the-zacks-analyst-blog-highlights-clovis-oncology-pfizer-roches-sanofi-and-regeneron-pharmaceuticals-cm731692,For Immediate Release Chicago IL January 10 2017 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the
CLVS,CLVS:UW,BBG001S2DKJ3,"The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals",2017-01-10 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-clovis-143002704.html,"The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regeneron Pharmaceuticals"
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme",2017-01-09 15:48:06 +0000,http://biz.yahoo.com/e/170109/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Present at the 35th Annual J.P. Morgan Healthcare Conference,2017-01-09 13:00:00 +0000,http://finance.yahoo.com/news/clovis-oncology-present-35th-annual-130000938.html,"[Business Wire] - Clovis Oncology, Inc. today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 2:30 PM Pacific Time."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock,2017-01-05 02:54:15 +0000,http://www.publicnow.com/view/3223B5C0C4C849B5DC1B8258009D2BD1283847A3,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Jan. 4, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Declares Pricing of Upsized Offering of Common Stock,2017-01-04 16:41:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w6ZKC-zkIAM/clovis-declares-pricing-of-upsized-offering-of-common-stock-cm729287,Clovis Oncology Inc CLVS announced the pricing of its underwritten public offering of common stock worth 5 million The company priced the shares at 41 00 each Notably the size of the offering was raised to 205 million from 175 million previously Clovis share price gained 40 1 in
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Declares Pricing of Upsized Offering of Common Stock,2017-01-04 14:43:02 +0000,http://finance.yahoo.com/news/clovis-declares-pricing-upsized-offering-144302664.html,Clovis Declares Pricing of Upsized Offering of Common Stock
CLVS,CLVS:UW,BBG001S2DKJ3,"Pre-Market Most Active for Jan 4, 2017 :  BBVA, SMI, AZN, NVO, LYG, TOT, CLVS, NVDA, NVLS, TVIX, AAPL, QQQ",2017-01-04 13:56:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6KjFAmrdiFE/pre-market-most-active-for-jan-4-2017-bbva-smi-azn-nvo-lyg-tot-clvs-nvda-nvls-tvix-aapl-qqq-cm729126,The NASDAQ 100 Pre Market Indicator is up 5 37 to 4 916 7 The total Pre Market volume is currently 9 286 372 shares traded The following are the most active stocks for the pre market session Banco Bilbao Viscaya Argentaria S A BBVA is 0 08 at 6 85 with 3 309
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock,2017-01-03 23:53:07 +0000,http://www.publicnow.com/view/FC01897885706F9B443297B1CC6B6099ED270A83,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Jan. 3, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.00 per ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Tuesday’s Biggest Biotech and Pharma Moves,2017-01-03 16:10:20 +0000,http://finance.yahoo.com/news/tuesday-biggest-biotech-pharma-moves-161020917.html,Tuesday’s Biggest Biotech and Pharma Moves
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Proposed Offering of Common Stock,2017-01-03 11:53:11 +0000,http://www.publicnow.com/view/8B117B52FA0687E9E06035FB5835B674AA093872,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Jan. 3, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate ..."
CLVS,CLVS:UW,BBG001S2DKJ3,17 Thoughts on Biotech Stocks to Kick Off 2017,2017-01-03 11:35:00 +0000,https://www.thestreet.com/story/13939672/1/17-thoughts-on-biotech-stocks-to-kick-off-2017.html?puc=yahoo&cm_ven=YAHOO,17 Thoughts on Biotech Stocks to Kick Off 2017
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech Stocks: What to Watch in 2017,2016-12-30 21:22:32 +0000,http://www.fool.com/investing/2016/12/29/biotech-stocks-what-to-watch-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech Stocks: What to Watch in 2017
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech Stocks: What to Watch in 2017,2016-12-29 22:57:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r53fbZDbezo/biotech-stocks-what-to-watch-in-2017-cm727678,This year has been a little rocky for biotech stocks In fact it s on pace to be the first decline for the sector in quite a few years But despite this year s decline for the sector there are plenty of individual biotech stocks with potential catalysts to help them rocket higher in
CLVS,CLVS:UW,BBG001S2DKJ3,Eight Milestones Of 2016 In The War On Cancer,2016-12-28 13:35:00 +0000,http://www.forbes.com/sites/arleneweintraub/2016/12/28/eight-milestones-of-2016-in-the-war-on-cancer/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Eight Milestones Of 2016 In The War On Cancer
CLVS,CLVS:UW,BBG001S2DKJ3,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,2016-12-27 19:32:56 +0000,http://finance.yahoo.com/news/expect-availability-biogens-newly-approved-193256344.html,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
CLVS,CLVS:UW,BBG001S2DKJ3,Growth-stock speculators need to tap the brakes here,2016-12-23 18:32:05 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=ADDF26B5-C65C-409B-BCAF-7446487274CB&siteid=yhoof2,Growth-stock speculators need to tap the brakes here
CLVS,CLVS:UW,BBG001S2DKJ3,2016's Worst Clinical Failures,2016-12-22 14:36:19 +0000,http://www.fool.com/investing/2016/12/21/2016s-worst-clinical-failures.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2016's Worst Clinical Failures
CLVS,CLVS:UW,BBG001S2DKJ3,Christmas Came Early for These Biotech Stocks,2016-12-22 12:21:25 +0000,http://www.fool.com/investing/2016/12/21/christmas-came-early-for-these-biotech-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Christmas Came Early for These Biotech Stocks
CLVS,CLVS:UW,BBG001S2DKJ3,Christmas Came Early for These Biotech Stocks,2016-12-21 22:57:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kEGir9Jg4IQ/christmas-came-early-for-these-biotech-stocks-cm724840,The week before Christmas is typically a slow time of the year for news releases a staple of biotech valuation changes But Clovis Oncology NASDAQ CLVS Akebia Therapeutics NASDAQ AKBA Merus NASDAQ MRUS and Ionis Pharmaceuticals NASDAQ IONS all had news
CLVS,CLVS:UW,BBG001S2DKJ3,4 stocks to watch,2016-12-21 20:26:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C4110C24-E519-47CB-B5BF-ECF53AE20878&siteid=yhoof2,4 stocks to watch
CLVS,CLVS:UW,BBG001S2DKJ3,4 Stocks With Technical Momentum,2016-12-21 19:22:30 +0000,http://finance.yahoo.com/news/4-stocks-technical-momentum-192230041.html,4 Stocks With Technical Momentum
CLVS,CLVS:UW,BBG001S2DKJ3,4 Stocks to Watch With Strong Technical Momentum,2016-12-21 18:12:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/okH63FBrXi8/4-stocks-to-watch-with-strong-technical-momentum-cm724737,"Here are four stocks with strong technical momentum.  Clovis Oncology Inc ( CLVS ) had a very good day on Tuesday, up 2.04, or 5%, to 42.52 on 4 million shares traded. The move closed the stock above lateral resistance at 40, and positioned it right at the top of the mini 2-month rising channel within its longer-term"
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Ovarian Cancer Drug Gets Priority Review After FDA OKs Clovis Med,2016-12-20 21:25:51 +0000,http://www.investors.com/news/technology/tesaro-drags-up-clovis-astrazeneca-on-fda-review-of-ovarian-cancer-med/,Tesaro Ovarian Cancer Drug Gets Priority Review After FDA OKs Clovis Med
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Scales 52-Week High on Early FDA Nod for Rubraca,2016-12-20 13:59:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nz5jkDvSYUU/clovis-scales-52-week-high-on-early-fda-nod-for-rubraca-cm723749,Clovis Oncology Inc s CLVS shares got a boost from an accelerated approval for its advanced ovarian cancer drug Rubraca rucaparib in the U S Notably the approval came more than two months ahead of schedule The FDA was expected to render a final decision on Rubraca by Feb 23
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Scales 52-Week High on Early FDA Nod for Rubraca,2016-12-20 12:17:12 +0000,http://finance.yahoo.com/news/clovis-scales-52-week-high-121712145.html,Clovis Scales 52-Week High on Early FDA Nod for Rubraca
CLVS,CLVS:UW,BBG001S2DKJ3,Surprise! Clovis Oncology Nabs Early OK,2016-12-20 02:56:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z20T9RlN8yk/surprise-clovis-oncology-nabs-early-ok-cm723690,The FDA has given a green light to Clovis Oncology s NASDAQ CLVS ovarian cancer drug Rubraca Its approval offers new hope to ovarian cancer patients who have seen their disease progress despite prior treatment and it positions Clovis Oncology to compete against
CLVS,CLVS:UW,BBG001S2DKJ3,Surprise! Clovis Oncology Nabs Early OK,2016-12-20 01:41:07 +0000,http://www.fool.com/investing/2016/12/19/surprise-clovis-oncology-nabs-early-ok.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Surprise! Clovis Oncology Nabs Early OK
CLVS,CLVS:UW,BBG001S2DKJ3,"Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars",2016-12-19 23:57:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tjLojRxRd_o/stock-market-roundup-dec-19-googl-bbry-self-driving-cars-clvs-soars-cm723639,While there was some afternoon volatility in international markets due to a pair of tragedies in Turkey and Germany the U S indexes were all green on Monday The headlines were dominated by news regarding self driving car projects from two separate tech giants as well as the FDA approval
CLVS,CLVS:UW,BBG001S2DKJ3,"Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars",2016-12-19 22:09:10 +0000,http://finance.yahoo.com/news/stock-market-roundup-dec-19-220910175.html,"Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars"
CLVS,CLVS:UW,BBG001S2DKJ3,US FDA clears ovarian cancer drug for hard-to-treat disease,2016-12-19 22:04:25 +0000,http://sg.finance.yahoo.com/news/us-fda-clears-ovarian-cancer-211343543.html,US FDA clears ovarian cancer drug for hard-to-treat disease
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Stock Rallies After AstraZeneca-Rivaling Ovarian Cancer Win,2016-12-19 21:26:57 +0000,http://www.investors.com/news/technology/clovis-stock-halted-after-astrazeneca-rivaling-ovarian-cancer-win/,Clovis Stock Rallies After AstraZeneca-Rivaling Ovarian Cancer Win
CLVS,CLVS:UW,BBG001S2DKJ3,Supernus Pharmaceuticals Breaks Out On Up Day For Biotech Stocks,2016-12-19 21:16:15 +0000,http://www.investors.com/news/technology/supernus-pharmaceuticls-breaks-out-on-up-day-for-biotech-stocks/,Supernus Pharmaceuticals Breaks Out On Up Day For Biotech Stocks
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why Clovis Oncology (CLVS) Stock Is Soaring Today,2016-12-19 20:57:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/47s6Mvm_658/heres-why-clovis-oncology-clvs-stock-is-soaring-today-cm723539,Shares of Clovis Oncology CLVS soared over 15 in morning trading Monday after the pharmaceutical company received approval for its new PARP inhibitor Rubraca which treats advanced ovarian cancer in women Today s approval is another example of the trend we are seeing in developing
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Wins Key FDA Approval on Ovarian Cancer Treatment,2016-12-19 20:53:29 +0000,http://finance.yahoo.com/news/clovis-wins-key-fda-approval-205329061.html,Clovis Wins Key FDA Approval on Ovarian Cancer Treatment
CLVS,CLVS:UW,BBG001S2DKJ3,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch",2016-12-19 20:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9I2-LeJFKKM/clvs-gets-fda-nod-pbyi-leaves-big-board-loxo-hits-alltime-high-cnat-on-watch-20161219-01000,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch"
CLVS,CLVS:UW,BBG001S2DKJ3,ADDING MULTIMEDIA and CONFERENCE CALL DETAILS Clovis Oncology Announces FDA Accelerated Approval of RUBRACA™ (rucaparib) for the Monotherapy Treatment of Advanced Ovarian Cancer in Women with Deleterious Germline or Somatic BRCA Mutations..,2016-12-19 20:01:08 +0000,http://www.publicnow.com/view/408396FF6EFEF1254BD64BD3028A411D7B2001AD,[at noodls] - http://www.businesswire.com/news/home/20161219006002/en/ BRCA Fact Sheet The corrected release reads: CLOVIS ONCOLOGY ANNOUNCES FDA ACCELERATED APPROVAL OF RUBRACA™ (RUCAPARIB) FOR THE MONOTHERAPY TREATMENT ...
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces FDA Accelerated Approval of RUBRACA™ (rucaparib) for the Monotherapy Treatment of Advanced Ovarian Cancer in Women with Deleterious Germline or Somatic BRCA Mutations Treated with Two or More Chemotherapies,2016-12-19 18:51:14 +0000,http://www.publicnow.com/view/1E41A2DAF0B5AEE6974EDC36FBDA6D21573A162D,"[at noodls] - http://www.businesswire.com/news/home/20161219006002/en/ 'Recurrent ovarian cancer remains one of the most difficult cancers to treat and for so many years, medical advances in this space have been limited,' ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why Clovis Oncology (CLVS) Stock Is Soaring Today,2016-12-19 18:50:06 +0000,http://finance.yahoo.com/news/heres-why-clovis-oncology-clvs-185006962.html,Here's Why Clovis Oncology (CLVS) Stock Is Soaring Today
CLVS,CLVS:UW,BBG001S2DKJ3,Stocks Higher As 3 Medicals Hit Buy Points; No 'Star Wars' Hasbro Bump,2016-12-19 18:48:48 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-higher-as-3-top-medical-stocks-hit-buy-points-no-star-wars-bump-for-hasbro/,Stocks Higher As 3 Medicals Hit Buy Points; No 'Star Wars' Hasbro Bump
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis's ovarian cancer drug wins accelerated FDA approval,2016-12-19 18:45:21 +0000,http://finance.yahoo.com/news/cloviss-ovarian-cancer-drug-wins-173015594.html,"[Reuters] - The U.S. Food and Drug Administration said it had granted accelerated approval to Clovis Oncology Inc's ovarian cancer drug in patients with a specific gene mutation whose disease advanced despite two or more rounds of chemotherapy. The drug, Rubraca, secured approval about two months earlier than expected for patients whose tumors have a specific gene mutation called BRCA, which is identified by an FDA-approved companion diagnostic test. The FDA on Monday also approved a diagnostic test made by Foundation Medicine Inc to detect the presence of BRCA gene mutations."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug,2016-12-19 17:21:00 +0000,http://www.thestreet.com/video/13931273/clovis-oncology-gets-fda-approval-for-new-ovarian-cancer-drug.html?puc=yahoov&cm_ven=YAHOOV,Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology's ovarian cancer treatment gets FDA OK,2016-12-19 16:56:16 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CBC7E354-08CC-4CBB-86F9-DA5123BE6FBB&siteid=yhoof2,Clovis Oncology's ovarian cancer treatment gets FDA OK
CLVS,CLVS:UW,BBG001S2DKJ3,FDA grants accelerated approval to Clovis's ovarian cancer drug,2016-12-19 16:27:18 +0000,http://finance.yahoo.com/news/fda-grants-accelerated-approval-cloviss-162718916.html,FDA grants accelerated approval to Clovis's ovarian cancer drug
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug,2016-12-19 16:16:00 +0000,https://www.thestreet.com/story/13931168/1/clovis-oncology-secures-fda-approval-for-new-ovarian-cancer-drug.html?puc=yahoo&cm_ven=YAHOO,Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
CLVS,CLVS:UW,BBG001S2DKJ3,Short-Sellers Are Betting Big Against Clovis Oncology -- Here's Why They're Probably Right,2016-12-13 17:58:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e7aC7BL_zdA/short-sellers-are-betting-big-against-clovis-oncology-heres-why-theyre-probably-right-cm720832,Shares of Clovis Oncology NASDAQ CLVS have risen nearly threefold since their summertime lows Despite the recent enthusiasm not everyone is optimistic about the cancer therapy developer s future Image source Getty Images A worrying 26 3 of the biotech s
CLVS,CLVS:UW,BBG001S2DKJ3,Short-Sellers Are Betting Big Against Clovis Oncology -- Here's Why They're Probably Right,2016-12-13 17:22:05 +0000,http://www.fool.com/investing/2016/12/13/short-sellers-are-betting-big-against-clovis-oncol.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Short-Sellers Are Betting Big Against Clovis Oncology -- Here's Why They're Probably Right
CLVS,CLVS:UW,BBG001S2DKJ3,Are Successful Investors Right To Be So Bearish on Synergy Resources Corp (SYRG)?,2016-12-09 20:20:29 +0000,http://www.insidermonkey.com/blog/are-successful-investors-right-to-be-so-bearish-on-synergy-resources-corp-syrg-504285/,Are Successful Investors Right To Be So Bearish on Synergy Resources Corp (SYRG)?
CLVS,CLVS:UW,BBG001S2DKJ3,Ariad Pharma Could Draw M&A Fire Ahead Of Second Cancer Drug Win,2016-12-07 21:32:38 +0000,http://www.investors.com/news/technology/ariad-pharma-could-draw-ma-fire-ahead-of-second-cancer-drug-win/,Ariad Pharma Could Draw M&A Fire Ahead Of Second Cancer Drug Win
CLVS,CLVS:UW,BBG001S2DKJ3,Here is What Hedge Funds Think About Gener8 Maritime Inc (GNRT),2016-12-05 10:54:07 +0000,http://www.insidermonkey.com/blog/here-is-what-hedge-funds-think-about-gener8-maritime-inc-gnrt-497752/,Here is What Hedge Funds Think About Gener8 Maritime Inc (GNRT)
CLVS,CLVS:UW,BBG001S2DKJ3,7 of the Most Shocking Biotech Pipeline Blowups of 2016,2016-12-04 18:04:17 +0000,http://www.fool.com/investing/2016/12/04/7-of-the-most-shocking-biotech-pipeline-blowups-of.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,7 of the Most Shocking Biotech Pipeline Blowups of 2016
CLVS,CLVS:UW,BBG001S2DKJ3,GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?,2016-12-01 17:21:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uv1EuhYbzQ8/gw-pharmaceuticals-gwph-what-awaits-in-q4-earnings-cm716383,GW Pharmaceuticals plc GWPH is scheduled to report fourth quarter fiscal 2016 results on Dec 5 before the opening bell The company has an impressive track record so far In fact in the four trailing quarters GW Pharma has surpassed estimates every time with an average positive surprise
CLVS,CLVS:UW,BBG001S2DKJ3,"Lifshitz & Miller Law Firm Announces Investigation of Adeptus Health Inc., Avid Technology, Inc., Cempra, Inc., Clovis Oncology, Inc., Impax Laboratories, Inc., Ligand Pharmaceuticals Incorporated, Pattern Energy Group Inc. and Kandi Techno",2016-12-01 16:44:00 +0000,http://finance.yahoo.com/news/lifshitz-miller-law-firm-announces-164400841.html,"[PR Newswire] - NEW YORK, Dec.1, 2016 /PRNewswire/ -- Adeptus Health Inc. (ADPT) Lifshitz & Miller announces investigation on behalf of ADPT investors concerning whether ADPT adequately disclosed its billing practices, ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Newman Ferrara LLP Announces Corporate Governance Investigation of Clovis Oncology Inc.,2016-11-30 19:25:00 +0000,http://finance.yahoo.com/news/newman-ferrara-llp-announces-corporate-192500156.html,[Business Wire] - Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Clovis Oncology Inc. focusing on potential breaches of fiduciary duty by the Company’s Board of Directors .
CLVS,CLVS:UW,BBG001S2DKJ3,Does Clovis Oncology Inc (CLVS) Represent a Good Addition to Your Portfolio?,2016-11-30 17:54:04 +0000,http://www.insidermonkey.com/blog/does-clovis-oncology-inc-clvs-represent-a-good-addition-to-your-portfolio-491756/,Does Clovis Oncology Inc (CLVS) Represent a Good Addition to Your Portfolio?
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016",2016-11-28 19:12:07 +0000,http://www.capitalcube.com/blog/index.php/clovis-oncology-inc-clvs-us-earnings-analysis-q3-2016-by-the-numbers-november-28-2016/,"Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016"
CLVS,CLVS:UW,BBG001S2DKJ3,Vetr Crowd Doesn't Like Outlook For Clovis Oncology,2016-11-23 20:44:07 +0000,http://finance.yahoo.com/news/vetr-crowd-doesnt-outlook-clovis-204407727.html,Vetr Crowd Doesn't Like Outlook For Clovis Oncology
CLVS,CLVS:UW,BBG001S2DKJ3,"Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According to a Recently Filed Lawsuit",2016-11-18 00:51:00 +0000,http://finance.yahoo.com/news/robbins-arroyo-llp-clovis-oncology-005100267.html,"[Business Wire] - Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Clovis Oncology, Inc. in the Supreme Court of the State of New York, County of New York."
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why These Biopharma Stocks Soared at Least 10% Today,2016-11-10 11:36:59 +0000,http://www.fool.com/investing/2016/11/09/heres-why-biopharma-stocks-soared-at-least-10-toda.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why These Biopharma Stocks Soared at Least 10% Today
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why These Biopharma Stocks Soared at Least 10% Today,2016-11-09 23:53:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IvJdPwL40Bg/heres-why-these-biopharma-stocks-soared-at-least-10-today-cm706843,Image source Getty Images What happened Many biopharma stocks are rising at least 10 today as investors are hopeful that the next president and more importantly the balance of power in Congress will not result in stricter regulations on the industry as many had appeared to
CLVS,CLVS:UW,BBG001S2DKJ3,"Westmoreland Coal Company (WLB), Corrections Corp Of America (CXW): Here’s Why Traders Are Piling Into These Stocks",2016-11-09 19:36:09 +0000,http://www.insidermonkey.com/blog/estmoreland-coal-company-wlb-corrections-corp-of-america-cxw-heres-why-traders-are-piling-into-these-stocks-486317/,"Westmoreland Coal Company (WLB), Corrections Corp Of America (CXW): Here’s Why Traders Are Piling Into These Stocks"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Stock Up on Narrower-than-Expected Q3 Loss,2016-11-07 12:31:12 +0000,http://finance.yahoo.com/news/clovis-clvs-stock-narrower-expected-123112960.html,Clovis (CLVS) Stock Up on Narrower-than-Expected Q3 Loss
CLVS,CLVS:UW,BBG001S2DKJ3,Six Late Stage Drugs That Bit The Dust Recently,2016-11-07 07:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7HZ5JOx7e_Y/six-late-stage-drugs-that-bit-the-dust-recently-20161107-00317,Six Late Stage Drugs That Bit The Dust Recently
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis 3Q Loss $66 Million or $1.70 a Share (CLVS),2016-11-05 14:07:00 +0000,http://www.investopedia.com/news/clovis-3q-loss-170share-beat-estimates-clvs/?partner=YahooSA,Clovis 3Q Loss $66 Million or $1.70 a Share (CLVS)
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report",2016-11-04 16:49:32 +0000,http://biz.yahoo.com/e/161104/clvs10-q.html,"CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report"
CLVS,CLVS:UW,BBG001S2DKJ3,Edited Transcript of CLVS earnings conference call or presentation 3-Nov-16 8:30pm GMT,2016-11-04 09:42:35 +0000,http://finance.yahoo.com/news/edited-transcript-clvs-earnings-conference-094235797.html,Edited Transcript of CLVS earnings conference call or presentation 3-Nov-16 8:30pm GMT
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis reports 3Q loss,2016-11-03 22:01:47 +0000,http://sg.finance.yahoo.com/news/clovis-reports-3q-loss-220147742.html,Clovis reports 3Q loss
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today,2016-11-03 20:30:00 +0000,http://biz.yahoo.com/cc/3/154593.html,Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update,2016-11-03 20:21:53 +0000,http://www.publicnow.com/view/2F1471CE6FF20855982CF024BB5CFF05B7059327,"[at noodls] - Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant ovarian cancer; PDUFA date February 23, 2017 Rucaparib MAA submission submitted this week Clovis ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh",2016-11-03 20:15:11 +0000,http://biz.yahoo.com/e/161103/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh"
CLVS,CLVS:UW,BBG001S2DKJ3,Q3 2016 Clovis Oncology Inc Earnings Release - After Market Close,2016-11-03 11:07:07 +0000,http://biz.yahoo.com/research/earncal/20161103.html?t=clvs,Q3 2016 Clovis Oncology Inc Earnings Release - After Market Close
CLVS,CLVS:UW,BBG001S2DKJ3,"Research Reports on Biotech Equities -- Mast Therapeutics, Array BioPharma, Galena Biopharma, and Clovis Oncology",2016-10-31 15:08:00 +0000,http://finance.yahoo.com/news/research-reports-biotech-equities-mast-150800017.html,"[PR Newswire] - Growing concerns that a victory by Democratic nominee Hillary Clinton in the presidential election will result in tighter regulations on pricing for new drugs, continues to disturb the Biotechnology arena, which has already tanked 15.53% this year, as per Investopedia data. Today, Stock-Callers.com reviews the performances of Mast Therapeutics Inc. (NYSE MKT: MSTX), Array BioPharma Inc. (ARRY), Galena Biopharma Inc. (GALE), and Clovis Oncology Inc. (CLVS) to see how they have fared over the last few trading sessions. Shares in California headquartered Mast Therapeutics Inc. ended Friday's session flat at $0.08 with a total trading volume of 2.78 million shares. Shares of the Company, which develops therapies for serious or life-threatening diseases with significant unmet needs, have a Relative Strength Index (RSI) of 32.10."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Present at the 2016 Credit Suisse Healthcare Conference,2016-10-31 12:30:00 +0000,http://finance.yahoo.com/news/clovis-oncology-present-2016-credit-123000588.html,"[Business Wire] - Clovis Oncology, Inc. today announced that Patrick Mahaffy, the Company’s President and CEO, will present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8, at 1:00pm MST."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Announce Third Quarter 2016 Financial Results and Host Webcast Conference Call on November 3,2016-10-27 12:56:03 +0000,http://www.publicnow.com/view/7832764AEDA556D166AC93EA3A5144A62D32E9A3,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Oct. 27, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.S. financial ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO",2016-10-12 12:39:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-alnylam-slumps-123912498.html,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Reaches Analyst Target Price,2016-10-11 14:17:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XqpGdnhusA4/clovis-oncology-reaches-analyst-target-price-cm691744,In recent trading shares of Clovis Oncology Inc Symbol CLVS have crossed above the average analyst 12 month target price of 31 83 changing hands for 32 44 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Inc. Is Flying High Today (and Could Go Higher From Here),2016-10-11 12:21:32 +0000,http://www.fool.com/investing/2016/10/10/could-tesaro-inc-be-ready-to-fly.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Tesaro Inc. Is Flying High Today (and Could Go Higher From Here)
CLVS,CLVS:UW,BBG001S2DKJ3,"Tesaro Bolts On Ovarian Cancer Win Vs. AstraZeneca, AbbVie",2016-10-10 20:12:24 +0000,http://www.investors.com/news/technology/tesaro-bolts-on-ovarian-cancer-win-vs-astrazeneca-abbvie/,"Tesaro Bolts On Ovarian Cancer Win Vs. AstraZeneca, AbbVie"
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Inc. Rose 52.7% in September,2016-10-10 18:19:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u7PLQNgX2Zs/why-clovis-oncology-inc-rose-527-in-september-cm691205,Image source Getty Images What Shares of Clovis Oncology NASDAQ CLVS a clinical stage biotech focused on cancer jumped more than 52 in September according to data from S amp P Global Market Intelligence CLVS data
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro Inc. Is Flying High Today (and Could Go Higher From Here),2016-10-10 18:19:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zXQ4Z0K8RMg/tesaro-inc-is-flying-high-today-and-could-go-higher-from-here-cm691201,Image source Getty Images If you re looking for a biotech 160 to 160 add high flying gains to 160 your portfolio 160 check out Tesaro Inc NASDAQ TSRO Tesaro 160 could be headed for lift off 160 after 160 rival Clovis Oncology NASDAQ CLVS 160
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Inc. Rose 52.7% in September,2016-10-10 16:45:41 +0000,http://www.fool.com/investing/2016/10/10/why-clovis-oncology-inc-rose-527-in-september.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Clovis Oncology Inc. Rose 52.7% in September
CLVS,CLVS:UW,BBG001S2DKJ3,3 Cancer Drugs That Could Get an FDA OK Next Year,2016-10-09 16:20:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PW6HQYKqJMg/3-cancer-drugs-that-could-get-an-fda-ok-next-year-cm690778,Image source Getty Images Significant spending on cancer research and development could be about to pay off for Clovis Oncology NASDAQ CLVS Array BioPharma NASDAQ ARRY and Ariad Pharmaceuticals NASDAQ ARIA All three of these companies are preparing for
CLVS,CLVS:UW,BBG001S2DKJ3,3 Cancer Drugs That Could Get an FDA OK Next Year,2016-10-09 15:13:33 +0000,http://www.fool.com/investing/2016/10/09/3-cancer-drugs-that-could-get-a-fda-ok-next-year.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Cancer Drugs That Could Get an FDA OK Next Year
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro's ovarian cancer drug benefits all patients in study,2016-10-08 08:33:45 +0000,http://finance.yahoo.com/news/tesaros-ovarian-cancer-drug-benefits-083345531.html,Tesaro's ovarian cancer drug benefits all patients in study
CLVS,CLVS:UW,BBG001S2DKJ3,Tesaro ovarian cancer drug shows broad benefits in study,2016-10-08 06:15:01 +0000,http://finance.yahoo.com/news/tesaro-ovarian-cancer-drug-shows-061501170.html,Tesaro ovarian cancer drug shows broad benefits in study
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Nose-Dives On Potentially Inferior Cancer Drug Vs. AstraZeneca,2016-10-07 20:16:45 +0000,http://www.investors.com/news/technology/clovis-nosedives-on-potentially-inferior-cancer-drug-vs-astrazeneca/,Clovis Nose-Dives On Potentially Inferior Cancer Drug Vs. AstraZeneca
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Shares Are Falling 14.5% Today,2016-10-07 19:43:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FZAByMAFN0s/why-clovis-oncology-shares-are-falling-145-today-cm690503,Image source Getty Images What happened After the company updated investors on the efficacy and safety of its ovarian cancer drug rucaparib shares in Clovis Oncology NASDAQ CLVS are tumbling by 14 5 at 2 p m EDT So what Rucaparib is in midstage studies evaluating its
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology (CLVS) Stock Tumbles on Trial Update, SunTrust Bullish",2016-10-07 19:11:00 +0000,https://www.thestreet.com/story/13846256/1/clovis-oncology-clvs-stock-tumbles-on-trial-update-suntrust-bullish.html?puc=yahoo&cm_ven=YAHOO,"Clovis Oncology (CLVS) Stock Tumbles on Trial Update, SunTrust Bullish"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis' Drug Data Deja Vu,2016-10-07 17:19:41 +0000,http://www.bloomberg.com/gadfly/articles/2016-10-07/clovis-rucaparib-data-d-j-vu-all-over-again?cmpid=yhoo.headline,Clovis' Drug Data Deja Vu
CLVS,CLVS:UW,BBG001S2DKJ3,"Notable Friday Option Activity: CLVS, TSN, ANF",2016-10-07 16:44:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mDZolzIwQF4/notable-friday-option-activity-clvs-tsn-anf-cm690395,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Clovis Oncology Inc Symbol CLVS where a total of 18 968 contracts have traded so far representing approximately 1 9 million underlying shares That amounts to about 43 5 of CLVS
CLVS,CLVS:UW,BBG001S2DKJ3,"Here’s Why These Five Stocks Are in the Red Today: Clovis Oncology, Tyson Foods, Lloyds Banking Group, and More",2016-10-07 16:13:11 +0000,http://www.insidermonkey.com/blog/heres-why-these-five-stocks-are-in-the-red-today-clovis-oncology-tyson-foods-lloyds-banking-group-and-more-479354/,"Here’s Why These Five Stocks Are in the Red Today: Clovis Oncology, Tyson Foods, Lloyds Banking Group, and More"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition,2016-10-07 14:28:00 +0000,https://www.thestreet.com/story/13845913/1/clovis-falls-on-fears-ovarian-cancer-drug-inferior-to-competition.html?puc=yahoo&cm_ven=YAHOO,Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress,2016-10-07 12:45:00 +0000,http://finance.yahoo.com/news/clovis-oncology-presents-efficacy-safety-124500704.html,[Business Wire] - Clovis Oncology announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement",2016-10-04 20:33:36 +0000,http://biz.yahoo.com/e/161004/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement"
CLVS,CLVS:UW,BBG001S2DKJ3,"Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates",2016-10-04 11:35:00 +0000,https://www.thestreet.com/story/13839500/1/investors-guide-to-this-week-s-clovis-tesaro-ovarian-cancer-drug-updates.html?puc=yahoo&cm_ven=YAHOO,"Investor's Guide to This Week's Clovis, Tesaro Ovarian Cancer Drug Updates"
CLVS,CLVS:UW,BBG001S2DKJ3,6 Best Performing Drug Stocks of September,2016-10-03 14:47:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5jt2X9_U-eY/6-best-performing-drug-stocks-of-september-cm687686,Pharma and biotech stocks have been under a lot of pressure over the last few quarters with the NYSE ARCA Pharmaceutical Index and the NASDAQ Biotechnology index declining 4 1 and 11 7 respectively so far in 2016 Factors like the drug pricing controversy and a changing competitive
CLVS,CLVS:UW,BBG001S2DKJ3,6 Best Performing Drug Stocks of September,2016-10-03 12:39:12 +0000,http://finance.yahoo.com/news/6-best-performing-drug-stocks-123912721.html,6 Best Performing Drug Stocks of September
CLVS,CLVS:UW,BBG001S2DKJ3,5 Top Performing Stocks of the Best ETF of Q3,2016-09-30 15:24:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1i38wrWT5co/5-top-performing-stocks-of-the-best-etf-of-q3-cm687111,After a huge sell off at the start of the year the biotech sector has made a strong comeback with BioShares Biotechnology Clinical Trials Fund BBC topping the list of the best performing ETFs of 3Q16 The fund delivered impressive returns of about 29 6 in the quarter and has a Zacks ETF Rank
CLVS,CLVS:UW,BBG001S2DKJ3,5 Top Performing Stocks of the Best ETF of Q3,2016-09-30 13:13:01 +0000,http://finance.yahoo.com/news/5-top-performing-stocks-best-131301185.html,5 Top Performing Stocks of the Best ETF of Q3
CLVS,CLVS:UW,BBG001S2DKJ3,"Health Care Sector Update for 09/28/2016: CLVS, KPTI",2016-09-28 14:01:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/srlHWGpwMiU/health-care-sector-update-for-09282016-clvs-kpti-cm685878,Top Health care stocks Top Health care stocks JNJ 0 2 JNJ 0 2 PFE 0 6 PFE 0 6 ABT 0 8 ABT 0 8 MRK 1 4 MRK 1 4 AMGN 0 7 AMGN 0 7 Health care shares were mainly higher in pre market trade Wednesday Health care shares were mainly higher in pre market trade Wednesday
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress,2016-09-28 11:55:00 +0000,http://finance.yahoo.com/news/clovis-oncology-announces-rucaparib-data-115500084.html,"[Business Wire] - Clovis Oncology, Inc. today announced that data from its rucaparib program in ovarian cancer will be presented at the annual European Society for Medical Oncology 2016 Congress."
CLVS,CLVS:UW,BBG001S2DKJ3,Moving Average Crossover Alert: Clovis Oncology (CLVS),2016-09-26 16:22:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BRXicuDu11M/moving-average-crossover-alert-clovis-oncology-clvs-cm684513,Clovis Oncology Inc CLVS is looking like an interesting pick from a technical perspective as the company is seeing favorable trends on the moving average crossover front Recently the 50 Day Moving Average for CLVS broke out above the 200 Day Simple Moving Average suggesting a short
CLVS,CLVS:UW,BBG001S2DKJ3,Moving Average Crossover Alert: Clovis Oncology (CLVS),2016-09-26 14:41:02 +0000,http://finance.yahoo.com/news/moving-average-crossover-alert-clovis-144102118.html,Moving Average Crossover Alert: Clovis Oncology (CLVS)
CLVS,CLVS:UW,BBG001S2DKJ3,3 Biotechs That Could Be M&A Targets,2016-09-24 17:20:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NmRMs_S2siU/3-biotechs-that-could-be-ma-targets-cm684176,Image source Getty Images After Pfizer Inc agreed to pay 14 times forecast sales for 2016 160 to acquire cancer drugmaking pure play Medivation last month shares in other cancer focused biotech companies shot higher While it doesn t make sense to buy shares in all
CLVS,CLVS:UW,BBG001S2DKJ3,3 Biotechs That Could Be M&A Targets,2016-09-24 16:09:27 +0000,http://www.fool.com/investing/2016/09/24/3-biotechs-that-could-be-ma-targets.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs That Could Be M&A Targets
CLVS,CLVS:UW,BBG001S2DKJ3,[video]Takeover Chatter Around Clovis May Be Overdone,2016-09-23 13:28:00 +0000,https://www.thestreet.com/story/13750094/1/takeover-chatter-around-clovis-may-be-overdone.html?puc=yahoo&cm_ven=YAHOO,[video]Takeover Chatter Around Clovis May Be Overdone
CLVS,CLVS:UW,BBG001S2DKJ3,"Why Clovis Oncology Inc (CLVS), Philip Morris International Inc. (PM) And Weyerhaeuser Co (WY) Are 3 of Today’s Best Stocks",2016-09-22 23:21:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DONK6D1xMpM/why-clovis-oncology-inc-clvs-philip-morris-international-inc-pm-and-weyerhaeuser-co-wy-are-3-of-todays-best-stocks-cm683515,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Ahead of the first presidential debate stocks rose So did gold perhaps indicating some concern about what will come of the debate Treasury yields also rose The S amp P
CLVS,CLVS:UW,BBG001S2DKJ3,4 health-care stocks to watch,2016-09-21 19:38:44 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CCF56263-1AE7-4530-9EE1-DE0ED3FFB8FB&siteid=yhoof2,4 health-care stocks to watch
CLVS,CLVS:UW,BBG001S2DKJ3,Here's Why Shares of Clovis Oncology Are Higher Wednesday,2016-09-21 15:52:00 +0000,http://www.thestreet.com/video/13747499/here-s-why-shares-of-clovis-oncology-are-higher-wednesday.html?puc=yahoov&cm_ven=YAHOOV,Here's Why Shares of Clovis Oncology Are Higher Wednesday
CLVS,CLVS:UW,BBG001S2DKJ3,"Why Traders Are Talking About Chevron, Adobe, Petrobras, and More",2016-09-21 15:16:07 +0000,http://www.insidermonkey.com/blog/why-traders-are-talking-about-chevron-adobe-petrobras-and-more-475849/,"Why Traders Are Talking About Chevron, Adobe, Petrobras, and More"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Charts Suggest Aggressive Buying,2016-09-21 14:31:00 +0000,http://realmoney.thestreet.com/articles/09/21/2016/clovis-oncology-charts-suggest-aggressive-buying?puc=yahoo&cm_ven=YAHOO,Clovis Oncology Charts Suggest Aggressive Buying
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology (CLVS) Stock Advances, Credit Suisse Upgrades",2016-09-21 13:56:00 +0000,https://www.thestreet.com/story/13747359/1/clovis-oncology-clvs-stock-advances-credit-suisse-upgrades.html?puc=yahoo&cm_ven=YAHOO,"Clovis Oncology (CLVS) Stock Advances, Credit Suisse Upgrades"
CLVS,CLVS:UW,BBG001S2DKJ3,Stocks Futures Buoyed by Bank of Japan Move on Long-Term Rates; Waiting For FOMC,2016-09-21 13:40:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dtJV2GLUadE/stocks-futures-buoyed-by-bank-of-japan-move-on-long-term-rates-waiting-for-fomc-cm682507,Stocks are set to open with sizable gains Wednesday as global investors react to the surprise move by the Bank of Japan to target long term interest rates and ahead of today s Federal Open Market Committee meeting Dow futures are 70 points above fair value with financial and consumer
CLVS,CLVS:UW,BBG001S2DKJ3,"Commit To Buy Clovis Oncology At $17.50, Earn 23.5% Annualized Using Options",2016-09-20 17:22:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BOChv8hBLQ4/commit-to-buy-clovis-oncology-at-1750-earn-235-annualized-using-options-cm682144,Investors considering a purchase of Clovis Oncology Inc Symbol CLVS stock but tentative about paying the going market price of 31 34 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the
CLVS,CLVS:UW,BBG001S2DKJ3,Gilead ready to shop?,2016-09-16 19:27:00 +0000,http://finance.yahoo.com/video/gilead-ready-shop-192700438.html,Gilead ready to shop?
CLVS,CLVS:UW,BBG001S2DKJ3,Can The Uptrend Continue for Clovis Oncology (CLVS)?,2016-09-15 17:18:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iUITQtKTp2A/can-the-uptrend-continue-for-clovis-oncology-clvs-cm680124,Investors certainly have to be happy with Clovis Oncology Inc CLVS and its short term performance After all the stock has jumped by 69 2 in the past 4 weeks and it is also above its 20 Day Simple Moving Average as well This is certainly a good trend but investors are probably
CLVS,CLVS:UW,BBG001S2DKJ3,Novavax And Three More Momentum Stocks Clear Resistance,2016-09-15 15:47:00 +0000,http://www.forbes.com/sites/greatspeculations/2016/09/15/novavax-and-three-more-momentum-stocks-clear-resistance/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Novavax And Three More Momentum Stocks Clear Resistance
CLVS,CLVS:UW,BBG001S2DKJ3,Can The Uptrend Continue for Clovis Oncology (CLVS)?,2016-09-15 15:10:03 +0000,http://finance.yahoo.com/news/uptrend-continue-clovis-oncology-clvs-151003915.html,Can The Uptrend Continue for Clovis Oncology (CLVS)?
CLVS,CLVS:UW,BBG001S2DKJ3,4 stocks to watch,2016-09-14 13:34:33 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C0CFD741-F9D3-4FAC-8CD0-AB43DD606B57&siteid=yhoof2,4 stocks to watch
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016",2016-09-13 19:17:20 +0000,http://www.capitalcube.com/blog/index.php/clovis-oncology-inc-clvs-us-earnings-analysis-q2-2016-by-the-numbers-september-13-2016/,"Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016"
CLVS,CLVS:UW,BBG001S2DKJ3,Why Gilead Sciences Loves PARP…And You Should Too,2016-09-13 17:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/13/why-gilead-sciences-loves-parp-and-you-should-too/?mod=yahoobarrons&ru=yahoo,Why Gilead Sciences Loves PARP…And You Should Too
CLVS,CLVS:UW,BBG001S2DKJ3,4 Momentum Stocks to Watch,2016-09-13 15:12:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dZFdV7kL0Sg/4-momentum-stocks-to-watch-cm678803,"By Harry Boxer   These four stocks have strong technical momentum.   Clovis Oncology, Inc.  ( CLVS ), which poppped nearly 30% three weeks ago and then flagged, broke out of the flag last week and looks to be consolidating ahead of its next up-move.  On Monday it gained 40 cents to 28.05 on strong volume of 2.8"
CLVS,CLVS:UW,BBG001S2DKJ3,Is Clovis Oncology Still a Strong Buy?,2016-09-12 16:33:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7D3Nsx2kBFk/is-clovis-oncology-still-a-strong-buy-cm678058,Image source Getty Images What happened Shares of Clovis Oncology NASDAQ CLVS a cancer focused biophama gained more than 64 for the month of August 160 according to data from S amp P Global Market Intelligence CLVS data
CLVS,CLVS:UW,BBG001S2DKJ3,Is Clovis Oncology Still a Strong Buy?,2016-09-12 15:59:47 +0000,http://www.fool.com/investing/2016/09/12/is-clovis-oncology-still-a-strong-buy.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Clovis Oncology Still a Strong Buy?
CLVS,CLVS:UW,BBG001S2DKJ3,[$$] Would Gilead Pick Up Tesaro's PARP?,2016-09-09 20:33:00 +0000,http://www.barrons.com/articles/would-gilead-pick-up-tesaros-parp-1473453221?mod=yahoobarrons&ru=yahoo,[$$] Would Gilead Pick Up Tesaro's PARP?
CLVS,CLVS:UW,BBG001S2DKJ3,Gilead Sciences: What is PARP?,2016-09-09 19:46:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/09/gilead-sciences-what-is-parp/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: What is PARP?
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis' Rucaparib Not to Face FDA Advisory Panel, Stock Up",2016-09-09 16:35:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U-Ge3EMvgtM/clovis-rucaparib-not-to-face-fda-advisory-panel-stock-up-cm677004,Clovis Oncology Inc s CLVS shares were up 15 after the company revealed in an 8 K filing that the FDA was not planning to not hold an advisory committee meeting to discuss the company s new drug application NDA for its experimental ovarian cancer treatment rucaparib We note that
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology (CLVS) in Focus: Stock Moves 15% Higher,2016-09-09 14:34:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gN8lhMfxPrI/clovis-oncology-clvs-in-focus-stock-moves-15-higher-cm676810,Clovis Oncology Inc CLVS was a big mover last session as its shares rose a little over 15 on the day The move came after the company disclosed in a SEC filing that the FDA is not planning an advisory committee meeting to discuss the company s New Drug Application or NDA for rucaparib
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis' Rucaparib Not to Face FDA Advisory Panel, Stock Up",2016-09-09 14:00:02 +0000,http://finance.yahoo.com/news/clovis-rucaparib-not-face-fda-140002405.html,"Clovis' Rucaparib Not to Face FDA Advisory Panel, Stock Up"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology (CLVS) in Focus: Stock Moves 15% Higher,2016-09-09 12:25:12 +0000,http://finance.yahoo.com/news/clovis-oncology-clvs-focus-stock-122512242.html,Clovis Oncology (CLVS) in Focus: Stock Moves 15% Higher
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Up As FDA Skips Review Panel For New Drug,2016-09-08 20:49:15 +0000,http://www.investors.com/news/technology/clovis-oncology-up-as-fda-skips-review-panel-for-new-drug/,Clovis Oncology Up As FDA Skips Review Panel For New Drug
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Inc. Is Soaring Today,2016-09-08 19:18:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DZcBVEra4Z8/why-clovis-oncology-inc-is-soaring-today-cm676461,Image source Getty Images What happened Shares of Clovis Oncology NASDAQ CLVS a cancer focused 160 drug developer were up by more than 15 as of 12 15 a m EDT after the company received some news from the U S Food amp Drug Administration related to its most
CLVS,CLVS:UW,BBG001S2DKJ3,Here's A Reason Why Clovis Oncology (CLVS) Stock Is Surging Today,2016-09-08 17:37:00 +0000,https://www.thestreet.com/story/13698933/1/here-s-a-reason-why-clovis-oncology-clvs-stock-is-surging-today.html?puc=yahoo&cm_ven=YAHOO,Here's A Reason Why Clovis Oncology (CLVS) Stock Is Surging Today
CLVS,CLVS:UW,BBG001S2DKJ3,Why Clovis Oncology Inc. Is Soaring Today,2016-09-08 17:21:09 +0000,http://www.fool.com/investing/2016/09/08/why-clovis-oncology-inc-is-soaring-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Clovis Oncology Inc. Is Soaring Today
CLVS,CLVS:UW,BBG001S2DKJ3,Here’s Why These Five Stocks Are Trading Higher Today,2016-09-08 17:16:41 +0000,http://www.insidermonkey.com/blog/heres-why-these-five-stocks-are-trading-higher-today-3-473017/,Here’s Why These Five Stocks Are Trading Higher Today
CLVS,CLVS:UW,BBG001S2DKJ3,When Gilead Sciences Speaks…,2016-09-08 17:08:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/08/when-gilead-sciences-speaks/?mod=yahoobarrons&ru=yahoo,When Gilead Sciences Speaks…
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Other Events",2016-09-08 13:18:54 +0000,http://biz.yahoo.com/e/160908/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Other Events"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Inc. (CLVS) Has Broken Out To An 8-Month High,2016-09-08 09:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yOJ5YhcBNSE/clovis-oncology-inc-clvs-has-broken-out-to-an-8month-high-20160908-00688,Clovis Oncology Inc. (CLVS) Has Broken Out To An 8-Month High
CLVS,CLVS:UW,BBG001S2DKJ3,"Kyle Bass Makes Huge Bet Against McDonald’s, Sells Off Clovis",2016-09-06 11:58:54 +0000,http://www.insidermonkey.com/blog/kyle-bass-makes-huge-bet-against-mcdonalds-sells-off-clovis-472423/,"Kyle Bass Makes Huge Bet Against McDonald’s, Sells Off Clovis"
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology Speeds Toward Possible Launch in Ovarian Cancer, but Red Flags Remain",2016-09-01 15:23:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2g5WihjsHa0/clovis-oncology-speeds-toward-possible-launch-in-ovarian-cancer-but-red-flags-remain-cm673404,Image Source Getty Images Shares of Clovis Oncology NASDAQ CLVS shot up more than 30 last week 160 on news that the Food and Drug Administration had accepted a New Drug Application or NDA for accelerated approval of rucaparib an ovarian cancer drug Rucaparib s fast
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology Speeds Toward Possible Launch in Ovarian Cancer, but Red Flags Remain",2016-09-01 13:50:59 +0000,http://www.fool.com/investing/2016/09/01/clovis-oncology-speeds-ahead-in-ovarian-cancer-but.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Clovis Oncology Speeds Toward Possible Launch in Ovarian Cancer, but Red Flags Remain"
CLVS,CLVS:UW,BBG001S2DKJ3,Here’s Why Many Smart Money Investors Are Bullish on Clovis Oncology,2016-08-31 15:26:44 +0000,http://www.insidermonkey.com/blog/heres-why-many-smart-money-investors-are-bullish-on-clovis-oncology-471284/,Here’s Why Many Smart Money Investors Are Bullish on Clovis Oncology
CLVS,CLVS:UW,BBG001S2DKJ3,Here's a Reason Why Clovis Oncology (CLVS) Stock Is Gaining Today,2016-08-31 15:06:00 +0000,https://www.thestreet.com/story/13690575/1/here-s-a-reason-why-clovis-oncology-clvs-stock-is-gaining-today.html?puc=yahoo&cm_ven=YAHOO,Here's a Reason Why Clovis Oncology (CLVS) Stock Is Gaining Today
CLVS,CLVS:UW,BBG001S2DKJ3,"Health Care Sector Update for 08/31/2016: VEEV,CLVS,PFE",2016-08-31 12:47:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cE2uoMnTqFk/health-care-sector-update-for-08312016-veevclvspfe-cm672664,"Top Health Care Stocks JNJ Unchanged PFE +1.3% MRK Unchanged ABT Unchanged AMGN Unchanged Health care stocks were little changed in Wednesday's early session, with shares of health care companies in the S&P 500 tracked by the Health Care"
CLVS,CLVS:UW,BBG001S2DKJ3,"Energy Sector Update for 08/31/2016: VEEV,CLVS,PFE",2016-08-31 12:27:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o78yr6peCk8/energy-sector-update-for-08312016-veevclvspfe-cm672653,"Top Energy Stocks JNJ Unchanged CVX Unchanged COP +0.59% SLB +0.20% OXY Unchanged Energy stocks were mostly steady in early Wednesday trading, with shares of energy companies in the S&P 500 unchanged. Crude oil for October delivery was down"
CLVS,CLVS:UW,BBG001S2DKJ3,Morning Movers: Clovis Amends Pfizer Agreement; H&R Block Tumbles,2016-08-31 12:23:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/31/morning-movers-clovis-amends-pfizer-agreement-hr-block-tumbles/?mod=yahoobarrons&ru=yahoo,Morning Movers: Clovis Amends Pfizer Agreement; H&R Block Tumbles
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement",2016-08-30 20:14:18 +0000,http://biz.yahoo.com/e/160830/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement"
CLVS,CLVS:UW,BBG001S2DKJ3,"Game On for Pfizer With $14 Billion Medivation Buyout (or, Why Pfizer's Buyout of Medivation Could Be a Smart Move)",2016-08-26 14:48:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A0xTlHfqZv4/game-on-for-pfizer-with-14-billion-medivation-buyout-or-why-pfizers-buyout-of-medivation-could-be-a-smart-move-cm670668,"Image source  Getty Images.  It's game on time for Pfizer (NYSE  PFE)    finally. On Monday, the giant pharma surprised the market by speeding past Sanofi (NYSE  SNY) to nab cancer"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis boosted by FDA acceptance of cancer drug,2016-08-25 16:15:10 +0000,http://www.bizjournals.com/denver/blog/boosters_bits/2016/08/clovis-boosted-by-fda-acceptance-of-cancer-drug.html?ana=yahoo,Clovis boosted by FDA acceptance of cancer drug
CLVS,CLVS:UW,BBG001S2DKJ3,5 Companies That Should Consider Kicking Their CEOs to the Curb,2016-08-25 13:48:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mgWA84WftTA/5-companies-that-should-consider-kicking-their-ceos-to-the-curb-cm669971,"Image source  Getty Images.  Chief Executive Officers, or CEOs, are the face of a company. They're supposed to be the rock solid leader that ensures a company's growth strategy remains on track, and"
CLVS,CLVS:UW,BBG001S2DKJ3,5 Companies That Should Consider Kicking Their CEOs to the Curb,2016-08-25 11:20:00 +0000,http://www.fool.com/investing/2016/08/25/5-companies-that-should-consider-kicking-their-ceo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Companies That Should Consider Kicking Their CEOs to the Curb
CLVS,CLVS:UW,BBG001S2DKJ3,"Why Best Buy Co Inc (BBY), Clovis Oncology Inc (CLVS) and Toll Brothers Inc (TOL) Are 3 of Today’s Best Stocks",2016-08-24 22:47:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vKumhx5TEnU/why-best-buy-co-inc-bby-clovis-oncology-inc-clvs-and-toll-brothers-inc-tol-are-3-of-todays-best-stocks-cm669335,"New home sales rose to the best levels in over nine years, and that was enough for investors to bid stocks higher Tuesday, although all"
CLVS,CLVS:UW,BBG001S2DKJ3,Our Take On The Clovis Oncology Inc (CLVS) Announcement,2016-08-24 19:03:33 +0000,http://www.insidermonkey.com/blog/our-take-on-the-clovis-oncology-inc-clvs-announcement-470412/,Our Take On The Clovis Oncology Inc (CLVS) Announcement
CLVS,CLVS:UW,BBG001S2DKJ3,"Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review",2016-08-24 18:09:06 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-medivation-pfizer-180906503.html,"Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review"
CLVS,CLVS:UW,BBG001S2DKJ3,7 Stocks Trading on Big Volume -- and What to Do With Them Now,2016-08-24 18:04:00 +0000,https://www.thestreet.com/story/13684257/1/7-stocks-trading-on-big-volume-and-what-to-do-with-them-now.html?puc=yahoo&cm_ven=YAHOO,7 Stocks Trading on Big Volume -- and What to Do With Them Now
CLVS,CLVS:UW,BBG001S2DKJ3,"News, Good or Bad, Can Create Buying Opportunities",2016-08-24 15:36:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OML52wzcrLQ/news-good-or-bad-can-create-buying-opportunities-cm669556,"Two very different stocks are in the news today, and for two very different reasons. Iconic furniture company La-Z-Boy ( LZB ) missed on earnings and is down significantly, while the biotech company Clovis Oncology ( CLVS ) got good news from the FDA and is spiking.  Despite the very different reactions to very"
CLVS,CLVS:UW,BBG001S2DKJ3,"How Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again",2016-08-24 14:25:24 +0000,http://247wallst.com/healthcare-business/2016/08/24/how-analysts-and-investors-are-chasing-clovis-higher-and-higher-all-over-again/,"How Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again"
CLVS,CLVS:UW,BBG001S2DKJ3,"Pre-Market Most Active for Aug 24, 2016 :  ERIC, NVO, AZN, EXPR, CLVS, LYG, BCS, LDOS, QQQ, OSUR, GPRO, XIV",2016-08-24 12:59:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AFWWSafUZRk/pre-market-most-active-for-aug-24-2016-eric-nvo-azn-expr-clvs-lyg-bcs-ldos-qqq-osur-gpro-xiv-cm669408,"The NASDAQ 100 Pre Market Indicator is up 1.11 to 4,819.59. The total Pre Market volume is currently 4,824,763 shares traded. The following are the most active stocks for the pre market session Ericsson ( ERIC ) is 0.0162"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Adding To Yesterday's Substantial Gain,2016-08-24 12:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y4Kqeli5ejo/clovis-oncology-adding-to-yesterdays-substantial-gain-20160824-00548,Clovis Oncology Adding To Yesterday's Substantial Gain
CLVS,CLVS:UW,BBG001S2DKJ3,"Top Analyst Upgrades and Downgrades: Clovis Oncology, Garmin, Lowe’s, NetApp, On Deck, Pioneer Natural, RSP Permian and More",2016-08-24 12:55:11 +0000,http://247wallst.com/investing/2016/08/24/top-analyst-upgrades-and-downgrades-clovis-oncology-garmin-lowes-netapp-on-deck-pioneer-natural-rsp-permian-and-more/,"Top Analyst Upgrades and Downgrades: Clovis Oncology, Garmin, Lowe’s, NetApp, On Deck, Pioneer Natural, RSP Permian and More"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Stock Up on FDA Priority Review for Rucaparib,2016-08-24 12:47:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wbAMs9CQN7w/clovis-clvs-stock-up-on-fda-priority-review-for-rucaparib-cm669367,"Clovis Oncology, Inc.'sCLVS shares shot up 27.2% on news that the FDA has granted priority review status to the company's regulatory application for its experimental cancer drug, rucaparib.  Clovis is looking to get rucaparib approved for"
CLVS,CLVS:UW,BBG001S2DKJ3,"Early movers: FIT, TSLA, PFE, LZB, CLVS, NMBL & more",2016-08-24 12:08:53 +0000,http://www.cnbc.com/id/103889463?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103889463,"Early movers: FIT, TSLA, PFE, LZB, CLVS, NMBL & more"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis (CLVS) Stock Up on FDA Priority Review for Rucaparib,2016-08-24 10:48:10 +0000,http://finance.yahoo.com/news/clovis-clvs-stock-fda-priority-104810321.html,Clovis (CLVS) Stock Up on FDA Priority Review for Rucaparib
CLVS,CLVS:UW,BBG001S2DKJ3,"LCI Vaults On Bright Outlook, OSUR Gets Zika Contract, CLVS To Face FDA In Feb.",2016-08-23 23:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VB9KpPjOIXs/lci-vaults-on-bright-outlook-osur-gets-zika-contract-clvs-to-face-fda-in-feb-20160823-00910,"LCI Vaults On Bright Outlook, OSUR Gets Zika Contract, CLVS To Face FDA In Feb."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis shares jump as FDA grants priority review to cancer treatment,2016-08-23 21:16:57 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=2B3CE8D5-11CE-43D8-85A6-0C04792FAC4E&siteid=yhoof2,Clovis shares jump as FDA grants priority review to cancer treatment
CLVS,CLVS:UW,BBG001S2DKJ3,Here's a Reason Why Clovis Oncology (CLVS) Stock Climbed Today,2016-08-23 20:49:00 +0000,https://www.thestreet.com/story/13683324/1/here-s-a-reason-why-clovis-oncology-clvs-stock-climbed-today.html?puc=yahoo&cm_ven=YAHOO,Here's a Reason Why Clovis Oncology (CLVS) Stock Climbed Today
CLVS,CLVS:UW,BBG001S2DKJ3,How Clovis Scored Big on a Milestone FDA Approval,2016-08-23 20:08:43 +0000,http://247wallst.com/healthcare-business/2016/08/23/how-clovis-scored-big-on-a-milestone-fda-approval/,How Clovis Scored Big on a Milestone FDA Approval
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis shares rocket after FDA decision,2016-08-23 19:30:04 +0000,http://www.cnbc.com/id/103888100?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103888100,Clovis shares rocket after FDA decision
CLVS,CLVS:UW,BBG001S2DKJ3,Here's why a small cancer company's shares are skyrocketing,2016-08-23 19:10:00 +0000,http://finance.yahoo.com/news/heres-why-small-cancer-companys-191000396.html,Here's why a small cancer company's shares are skyrocketing
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Jumps as Cancer Drug Gets Priority for FDA Review,2016-08-23 19:03:44 +0000,http://www.bloomberg.com/news/articles/2016-08-23/clovis-jumps-after-cancer-drug-gets-fast-track-for-fda-approval?cmpid=yhoo.headline,Clovis Jumps as Cancer Drug Gets Priority for FDA Review
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Jumps After Cancer Drug Gets Fast Track for FDA Approval,2016-08-23 19:03:44 +0000,http://finance.yahoo.com/news/clovis-jumps-cancer-drug-gets-190344991.html,Clovis Jumps After Cancer Drug Gets Fast Track for FDA Approval
CLVS,CLVS:UW,BBG001S2DKJ3,FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer,2016-08-23 18:58:02 +0000,http://www.publicnow.com/view/6E46CF7E258C2E78A63CB8F1EAB6269E3241A2B9,"[at noodls] - Seeking approval for mutant BRCA patients treated with two or more prior therapies FDA Grants Priority Review Status Assigns PDUFA Date of February 23, 2017 BOULDER, Colo.--(BUSINESS WIRE)--Aug. 23, 2016-- ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Shares of Clovis surge on positive FDA news,2016-08-23 18:40:00 +0000,http://finance.yahoo.com/video/shares-clovis-surge-positive-fda-184000226.html,Shares of Clovis surge on positive FDA news
CLVS,CLVS:UW,BBG001S2DKJ3,Biotech stocks rally as investors bet on the next big tie-up,2016-08-22 15:57:44 +0000,http://www.cnbc.com/id/103884606?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103884606,Biotech stocks rally as investors bet on the next big tie-up
CLVS,CLVS:UW,BBG001S2DKJ3,"Noteworthy Friday Option Activity: CLVS, FEYE, LVS",2016-08-19 20:46:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DvdKDr6_9ZA/noteworthy-friday-option-activity-clvs-feye-lvs-cm667937,"Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Clovis Oncology Inc (Symbol CLVS), where a total of 5,191 contracts have traded so far, representing approximately 519,100 underlying shares. That amounts"
CLVS,CLVS:UW,BBG001S2DKJ3,Can The Uptrend Continue for Clovis Oncology (CLVS)?,2016-08-18 15:49:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kcClzJTm1VI/can-the-uptrend-continue-for-clovis-oncology-clvs-cm667087,"Investors certainly have to be happy with Clovis Oncology, Inc.CLVS and its short term performance. After all, the stock has jumped by 18.2% in the past 4 weeks, and it is also above its 20 Day Simple"
CLVS,CLVS:UW,BBG001S2DKJ3,Can The Uptrend Continue for Clovis Oncology (CLVS)?,2016-08-18 13:58:01 +0000,http://finance.yahoo.com/news/uptrend-continue-clovis-oncology-clvs-135801998.html,Can The Uptrend Continue for Clovis Oncology (CLVS)?
CLVS,CLVS:UW,BBG001S2DKJ3,A Closer Look at Five Stocks in Spotlight Following Financial Reports,2016-08-09 16:03:13 +0000,http://www.insidermonkey.com/blog/a-closer-look-at-five-stocks-in-spotlight-following-financial-reports-468086/,A Closer Look at Five Stocks in Spotlight Following Financial Reports
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report",2016-08-09 10:12:56 +0000,http://biz.yahoo.com/e/160809/clvs10-q.html,"CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today,2016-08-08 20:30:00 +0000,http://biz.yahoo.com/cc/8/153188.html,Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update,2016-08-08 20:18:11 +0000,http://www.publicnow.com/view/ADD6A06D150F8CDC1A0ECE2766E8760F8B358B39,[at noodls] - Rucaparib NDA submission completed in late June for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors FDA decision on filing and determination of PDUFA date is anticipated ...
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis reports 2Q loss,2016-08-08 20:11:44 +0000,http://sg.finance.yahoo.com/news/clovis-reports-2q-loss-201144872.html,Clovis reports 2Q loss
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh",2016-08-08 20:08:26 +0000,http://biz.yahoo.com/e/160808/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh"
CLVS,CLVS:UW,BBG001S2DKJ3,Q2 2016 Clovis Oncology Inc Earnings Release - After Market Close,2016-08-08 11:07:03 +0000,http://biz.yahoo.com/research/earncal/20160808.html?t=clvs,Q2 2016 Clovis Oncology Inc Earnings Release - After Market Close
CLVS,CLVS:UW,BBG001S2DKJ3,"Notable Friday Option Activity: QVCA, CLVS, HOS",2016-08-05 21:15:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/esmo0aAVF70/notable-friday-option-activity-qvca-clvs-hos-cm661327,"Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Liberty Interactive Corp Liberty Ventures Com Ser B (Symbol QVCA), where a total of 19,713 contracts have traded so far, representing approximately"
CLVS,CLVS:UW,BBG001S2DKJ3,7 Biotech Stocks With Pivotal Catalysts in 2017,2016-08-02 22:56:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-zs3zLoW4Ww/7-biotech-stocks-with-pivotal-catalysts-in-2017-cm659176,"When it comes to biotech stocks, it's no secret that regulatory and clinical catalysts can generate enormous returns    or losses    for investors in the blink of an eye. With this in"
CLVS,CLVS:UW,BBG001S2DKJ3,"Tuesday's ETF Movers: GDX, XBI",2016-08-02 18:51:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OisiZ5nyjQ4/tuesdays-etf-movers-gdx-xbi-cm659039,"In trading on Tuesday, the Gold Miners ETF ( GDX ) is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of Osisko Gold Royalties (OR.CA), up about 6.9% and"
CLVS,CLVS:UW,BBG001S2DKJ3,The Math Shows IYH Can Go To $172,2016-08-01 13:56:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1yyQPilzUhE/the-math-shows-iyh-can-go-to-172-cm657915,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8,2016-07-26 20:28:16 +0000,http://www.publicnow.com/view/A5ECC9CFD55B1B30B3B588F0068C74DCBD94FE16,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Jul. 26, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2016 financial results on Monday, August 8, 2016, after the close of the U.S. financial ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Coverage Initiated on Select Biotech Equities,2016-07-11 12:58:41 +0000,http://news.investornetwork.com/2016/07/11/coverage-initiated-on-select-biotech-equities/?1=1&1468241921,Coverage Initiated on Select Biotech Equities
CLVS,CLVS:UW,BBG001S2DKJ3,3 Shocking Biotech Flops of 2016 So Far,2016-07-08 15:40:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x-WAZ6eD2TA/3-shocking-biotech-flops-of-2016-so-far-cm646381,Image source  Getty  Most investors in clinical stage biotech stocks are aware that odds of success are heavily stacked against them. It has been estimated that 90% of compounds that enter clinical trials will
CLVS,CLVS:UW,BBG001S2DKJ3,3 Shocking Biotech Flops of 2016 So Far,2016-07-08 14:04:00 +0000,http://www.fool.com/investing/2016/07/08/3-shocking-biotech-flops-of-2016-so-far.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Shocking Biotech Flops of 2016 So Far
CLVS,CLVS:UW,BBG001S2DKJ3,Buyout target Medivation says cancer drug could be 'best in class',2016-07-07 01:14:20 +0000,http://uk.finance.yahoo.com/news/buyout-target-medivation-says-cancer-011420113.html,Buyout target Medivation says cancer drug could be 'best in class'
CLVS,CLVS:UW,BBG001S2DKJ3,An Overnight Double! Could These Drugmakers Be Next?,2016-07-01 21:50:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S2lhNqLHwZg/an-overnight-double-could-these-drugmakers-be-next-cm644067,"Image source  Getty Images.  Tesaro (NASDAQ  TSRO) saw its shares increase 108% on Wednesday after announcing that its cancer drug, niraparib, extended progression free survival    a measure of how"
CLVS,CLVS:UW,BBG001S2DKJ3,An Overnight Double! Could These Drugmakers Be Next?,2016-07-01 19:40:00 +0000,http://www.fool.com/investing/2016/07/01/an-overnight-double-could-these-drugmakers-be-next.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,An Overnight Double! Could These Drugmakers Be Next?
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology (CLVS) Jumps: Stock Adds 21.9% in Session,2016-06-30 13:54:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/adi9Po17JBo/clovis-oncology-clvs-jumps-stock-adds-219-in-session-cm643244,"Clovis Oncology, Inc.CLVS was a big mover last session, as its shares rose almost 22% on the day. The upside followed the release of Tesaro, Inc.'s TSRO positive Phase 3 clinical trial results for Niraparib, a PARP inhibitor. Clovis"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology (CLVS) Jumps: Stock Adds 21.9% in Session,2016-06-30 12:15:12 +0000,http://finance.yahoo.com/news/clovis-oncology-clvs-jumps-stock-121512946.html,Clovis Oncology (CLVS) Jumps: Stock Adds 21.9% in Session
CLVS,CLVS:UW,BBG001S2DKJ3,"Why Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today’s Best Stocks",2016-06-30 04:47:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cFbku0d0k9A/why-tesaro-inc-tsro-clovis-oncology-inc-clvs-and-twilio-inc-twlo-are-3-of-todays-best-stocks-cm643044,"The stock market continued to rally Wednesday, as oil got its mojo back to the tune of 3% plus.   By the day's end, the "
CLVS,CLVS:UW,BBG001S2DKJ3,What's Causing Clovis Oncology Shares to Skyrocket Today?,2016-06-29 19:48:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H4RhBbIJHeE/whats-causing-clovis-oncology-shares-to-skyrocket-today-cm642840,"Image source  Clovis Oncology.  What  After Tesaro (NASDAQ  TSRO) reported that its PARP inhibitor successfully improved patient outcomes in a late stage ovarian cancer trial, shares in Clovis Oncology (NASDAQ"
CLVS,CLVS:UW,BBG001S2DKJ3,What's Causing Clovis Oncology Shares to Skyrocket Today?,2016-06-29 18:22:00 +0000,http://www.fool.com/investing/2016/06/29/whats-causing-clovis-oncology-shares-to-skyrocket.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,What's Causing Clovis Oncology Shares to Skyrocket Today?
CLVS,CLVS:UW,BBG001S2DKJ3,16 Biopharma Companies Besides Medivation That Are Attractive Targets,2016-06-29 17:28:00 +0000,https://www.thestreet.com/story/13624716/1/16-biopharma-companies-besides-medivation-that-are-attractive-targets.html?puc=yahoo&cm_ven=YAHOO,16 Biopharma Companies Besides Medivation That Are Attractive Targets
CLVS,CLVS:UW,BBG001S2DKJ3,Here’s Why These Five Stocks Are On the Move on Wednesday,2016-06-29 15:49:30 +0000,http://www.insidermonkey.com/blog/heres-why-these-five-stocks-are-on-the-move-on-wednesday-462493/,Here’s Why These Five Stocks Are On the Move on Wednesday
CLVS,CLVS:UW,BBG001S2DKJ3,These 15 Biotech Companies Could Be Takeover Targets,2016-06-29 15:06:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/06/29/these-15-companies-could-be-takeover-targets/?mod=yahoobarrons&ru=yahoo,These 15 Biotech Companies Could Be Takeover Targets
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Inc. (CLVS) Is Surging In Early Trade,2016-06-29 09:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jTEuCtWcXJ8/clovis-oncology-inc-clvs-is-surging-in-early-trade-20160629-00531,Clovis Oncology Inc. (CLVS) Is Surging In Early Trade
CLVS,CLVS:UW,BBG001S2DKJ3,5 Reasons to Hate Biotech Stocks,2016-06-23 15:03:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/feWObTUEQZ4/5-reasons-to-hate-biotech-stocks-cm639520,"Image source  Getty Images.  The biotechnology industry is exciting, full of hope and many great successes and failures. It holds the potential to cure cancer and other dreaded diseases    which"
CLVS,CLVS:UW,BBG001S2DKJ3,5 Reasons to Hate Biotech Stocks,2016-06-23 13:04:00 +0000,http://www.fool.com/investing/2016/06/23/5-reasons-to-hate-biotech-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Reasons to Hate Biotech Stocks
CLVS,CLVS:UW,BBG001S2DKJ3,Investors Win When Boring Beats Sexy (XLU),2016-06-21 20:57:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yPkEMrxAV10/investors-win-when-boring-beats-sexy-xlu-cm638669,"Higher investment risk leads to higher investment returns, right? It's a Wall Street axiom that we've heard so many times it's become ingrained in us."
CLVS,CLVS:UW,BBG001S2DKJ3,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders",2016-06-10 12:32:10 +0000,http://biz.yahoo.com/e/160610/clvs8-k.html,"CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting,2016-06-06 12:48:01 +0000,http://www.publicnow.com/view/AAF6B53E67B6238449DBF2BE00862957ADF1F2C1,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Jun. 6, 2016-- Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Redmile Group Sticking With Healthcare Picks After Rough Q1,2016-06-03 13:30:12 +0000,http://www.insidermonkey.com/blog/redmile-group-sticking-with-healthcare-picks-after-rough-q1-457487/,Redmile Group Sticking With Healthcare Picks After Rough Q1
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016",2016-06-01 21:04:40 +0000,http://www.capitalcube.com/blog/index.php/clovis-oncology-inc-clvs-us-earnings-analysis-q1-2016-by-the-numbers-june-1-2016/,"Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting,2016-05-19 20:52:01 +0000,http://www.publicnow.com/view/C11DBD183DC00A1EC0A449A0123B5D43AF818937,[at noodls] - New rucaparib data to be highlighted in poster presentations Rolling New Drug Application (NDA) submission for rucaparib for the treatment of patients with advanced ovarian cancer expected to complete ...
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis reports 1Q loss,2016-05-05 21:48:37 +0000,http://sg.finance.yahoo.com/news/clovis-reports-1q-loss-214837599.html,Clovis reports 1Q loss
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Q1 2016 Operating Results and Corporate Update,2016-05-05 20:21:29 +0000,http://www.publicnow.com/view/CBD83C2D5BB835EDFA7DE081293644F246AB706E,[at noodls] - Rucaparib rolling NDA submission initiated for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors and expected to complete Q2 2016 Rucaparib MAA submission planned ...
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Announce First Quarter 2016 Financial Results and Host Webcast Conference Call on May 5,2016-04-26 12:38:07 +0000,http://www.publicnow.com/view/3C044A926AA48D5AA89E44339C2C2B8F58AC0121,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Apr. 26, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S. financial ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Surprising Analyst 12-Month Target For IYH,2016-04-19 14:00:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lNavkOZLt80/surprising-analyst-12-month-target-for-iyh-cm608126,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
CLVS,CLVS:UW,BBG001S2DKJ3,"The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma",2016-04-14 15:30:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vyInDXs7FBY/the-zacks-analyst-blog-highlights-intercept-clovis-abbvie-relypsa-and-horizon-pharma-cm606247,"For Immediate Release Chicago, IL April 14, 2016 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks"
CLVS,CLVS:UW,BBG001S2DKJ3,"Clovis Drops, FDA Panel Seeks More Data on Rociletinib",2016-04-14 14:27:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gU6z2L2E5f8/clovis-drops-fda-panel-seeks-more-data-on-rociletinib-cm606319,"Clovis Oncology, Inc. 's CLVS shares plunged to a new 52 week low of $12.25 on Apr 12 and eventually closed at $14.24 with the FDA's Oncologic Drugs Advisory Committee asking the company for additional data on its experimental"
CLVS,CLVS:UW,BBG001S2DKJ3,"Why Clovis Oncology Inc (CLVS), Seagate Technology PLC (STX) and Sprint Corp (S) Are 3 of Today’s Worst Stocks",2016-04-14 03:32:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V7wYsj2hAms/why-clovis-oncology-inc-clvs-seagate-technology-plc-stx-and-sprint-corp-s-are-3-of-todays-worst-stocks-cm606127,"Following through on Tuesday's bullishness, stocks made another impressive gain today. In fact, the S&P 500 's 1.0% advance to 2084.42 left it at the"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Provides Update on FDA Oncologic Drugs Advisory Committee Meeting to Review Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer,2016-04-12 18:14:25 +0000,http://www.publicnow.com/view/0A6CDA4E6DC5C0D958F0D3E7AC49602EA4FD42C5,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Apr. 12, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"Trading of Clovis Oncology, Inc. Common Stock Halted",2016-04-12 11:24:15 +0000,http://www.publicnow.com/view/3546BE424E158BA6E4A230073464DC76DC2313C2,"[at noodls] - FDA's Oncologic Drugs Advisory Committee to Review Rociletinib New Drug Application for the Treatment of Non-Small Cell Lung Cancer BOULDER, Colo.--(BUSINESS WIRE)--Apr. 12, 2016-- Clovis Oncology, Inc. ..."
CLVS,CLVS:UW,BBG001S2DKJ3,FDA Posts Briefing Documents for Advisory Committee Meeting to Review Clovis Oncology’s Rociletinib for Treatment of Advanced T790M-Positive Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer,2016-04-08 12:57:25 +0000,http://www.publicnow.com/view/CDF628A916DFB9D8A41EBA91D4D9BE92AFAB5126,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Apr. 8, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) posted briefing materials in advance of the Oncologic ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis reports 4Q loss,2016-02-25 23:13:49 +0000,http://sg.finance.yahoo.com/news/clovis-reports-4q-loss-231349834.html,Clovis reports 4Q loss
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Initiates Immunotherapy Combination Trial,2016-01-27 13:26:36 +0000,http://www.publicnow.com/view/63E022F3F10BF3D99C7A7E0F949F5F62BC9F926D,"[at noodls] - Study to evaluate the combination of rociletinib (CO-1686) with Genentech's atezolizumab (MPDL3280A) for patients with advanced EGFR-mutant non-small cell lung cancer --(BUSINESS WIRE)--Jan. 27, 2016-- ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Appoints Dale Hooks as Chief Commercial Officer,2016-01-25 13:07:17 +0000,http://www.publicnow.com/view/BA58AA22BBAD5490E317E2896E95AC7F57155708,"[at noodls] - Hooks, Clovis' Vice President of Sales since 2014, has been instrumental in building out the Company's commercial organization --(BUSINESS WIRE)--Jan. 25, 2016-- (NASDAQ: CLVS) announced today that has ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Present at the 34th Annual J.P. Morgan Healthcare Conference,2016-01-06 13:12:12 +0000,http://www.noodls.com/view/87189F1C5515381C8BA1CBEC18DB6E12D9DF54E7,"[at noodls] - --(BUSINESS WIRE)--Jan. 6, 2016-- (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, , will present at the 34th Annual on at . The conference will be held at the in . A live ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Receives Notification of PDUFA Extension for Rociletinib,2015-12-15 21:34:16 +0000,http://www.noodls.com/view/1579586897C5A3C5F93526DA308DA50370DD5FA2,"[at noodls] - PDUFA goal date extended by three months to --(BUSINESS WIRE)--Dec. 15, 2015-- (NASDAQ: CLVS) announced today that the () has extended the Prescription Drug User Fee Act (PDUFA) date for Clovis' New Drug ..."
CLVS,CLVS:UW,BBG001S2DKJ3,"AstraZeneca's Tagrisso to cost $12,750 for a month's supply",2015-11-17 13:08:06 +0000,http://uk.finance.yahoo.com/news/astrazenecas-tagrisso-cost-12-750-130806396.html,"AstraZeneca's Tagrisso to cost $12,750 for a month's supply"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology sinks as FDA seeks more information on drug,2015-11-16 22:20:31 +0000,http://sg.finance.yahoo.com/news/clovis-oncology-sinks-fda-seeks-150433476.html,Clovis Oncology sinks as FDA seeks more information on drug
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Regulatory Update for Rociletinib NDA Filing,2015-11-16 13:45:06 +0000,http://www.noodls.com/view/91EAC648F11D41961A97F7FE87DAAA0A1A667E13,"[at noodls] - Mid-Cycle Communication Meeting with FDA completed Additional clinical information for 500mg and 625mg BID dose groups to be provided by the Company today BOULDER, Colo.--(BUSINESS WIRE)--Nov. 16, 2015-- ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis reports 3Q loss,2015-11-05 23:48:31 +0000,http://sg.finance.yahoo.com/news/clovis-reports-3q-loss-234831962.html,Clovis reports 3Q loss
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Third Quarter 2015 Operating Results,2015-11-05 21:41:06 +0000,http://www.noodls.com/view/508EB2E48B66413D95D8B541715E58160DBFA4E4,[at noodls] - New Drug Application (NDA) for rociletinib for the treatment of advanced EGFR-mutant T790M+ non-small cell lung cancer (NSCLC) on file with U.S. FDA Marketing Authorization Application (MAA) for rociletinib ...
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Present at the 2015 Credit Suisse Healthcare Conference,2015-11-03 14:16:03 +0000,http://www.noodls.com/view/AE658E3A0FD4D6EC03695F5E12C18ADC552E9013,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Nov. 3, 2015-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T. Mast, the Company's Executive Vice President and CFO, will present at the 2015 Credit Suisse ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Data Presentations at 2015 European Cancer Congress,2015-09-23 12:45:20 +0000,http://www.noodls.com/view/89226FEFC67E2F47139A0432E2B43D79CCEC19B2,"[at noodls] - Three oral presentations and four scientific posters selected for presentation at the European Cancer Congress in Vienna, Austria Rucaparib oral presentation on Tuesday, September 29 to include final outcomes ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference 2015,2015-09-10 13:16:04 +0000,http://www.noodls.com/view/B7D4D68FD9F25F36008069385648F608CC837C03,"[at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Sep. 10, 2015-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the Morgan Stanley ..."
CLVS,CLVS:UW,BBG001S2DKJ3,BUZZ-Clovis Oncology's lung cancer drug can compete with AstraZeneca's - analysts,2015-09-09 17:44:15 +0000,http://uk.finance.yahoo.com/news/buzz-clovis-oncologys-lung-cancer-174415704.html,BUZZ-Clovis Oncology's lung cancer drug can compete with AstraZeneca's - analysts
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis Oncology Announces Data Presentations at 16th World Conference on Lung Cancer,2015-09-04 10:35:05 +0000,http://www.noodls.com/view/80FF6AF7F4E8C9C82A73EB75438390B0D5A126FF,"[at noodls] - Four rociletinib mini-oral presentations and two scientific posters debuting at World Conference on Lung Cancer in Denver BOULDER, Colo.--(BUSINESS WIRE)--Sep. 4, 2015-- Clovis Oncology (NASDAQ:CLVS) today ..."
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis gets breakthrough status for ovarian cancer drug,2015-04-06 21:04:35 +0000,http://sg.finance.yahoo.com/news/clovis-gets-breakthrough-status-ovarian-210435644.html,Clovis gets breakthrough status for ovarian cancer drug
CLVS,CLVS:UW,BBG001S2DKJ3,"AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer",2014-11-18 14:38:45 +0000,http://uk.finance.yahoo.com/news/astrazeneca-trumpets-standalone-strength-drug-081205221.html,"AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer"
CLVS,CLVS:UW,BBG001S2DKJ3,Clovis misses 3Q profit forecasts,2014-11-07 00:39:55 +0000,http://sg.finance.yahoo.com/news/clovis-misses-3q-profit-forecasts-003955802--finance.html,Clovis misses 3Q profit forecasts
CLVS,CLVS:UW,BBG001S2DKJ3,Cancer drug setback tarnishes AstraZeneca's R&D claims,2014-06-26 10:35:23 +0000,http://sg.finance.yahoo.com/news/cancer-drug-setback-tarnishes-astrazenecas-103523872.html,Cancer drug setback tarnishes AstraZeneca's R&D claims
